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                                                                 ABSTRACT 
TITLE: ISOLATION AND CHARACTERIZATION OF BACTERIAL 
PATHOGENS CAUSING ASYMPTOMATIC BACTERIURIA IN 
ANTENATAL WOMEN ATTENDING TERTIARY CARE HOSPITAL  
INTRODUCTION 
                    Urinary tract infections (UTI) are one of the most prevalent bacterial 
infections and the significant cause of morbidity and mortality. Urinary tract infection 
is mainly a disease of the females, due to the anatomy of the female urethra. 
Escherichia coli are responsible for 50%-90% of infections. The gold standard 
screening test for asymptomatic bacteriuria is the urine culture. The management of 
asymptomatic bacteriuria in pregnancy promptly reduces the perinatal complications. 
AIMS  
1. To isolate and characterize the bacterial pathogens causing asymptomatic 
bacteriuria in antenatal women.  
2. To determine the antibiotic sensitivity pattern of the isolates, ESBL and MRSA 
detection. 
MATERIALS AND METHODS 
            1000 antenatal women were screened for asymptomatic bacteriuria at 
Government Kilpauk Medical College and Hospital. Urine specimens were collected 
by mid-stream clean catch method and processed immediately. To isolate the 
organism, a semi-quantitative calibrated loop technique was used. The virulence 
factors of the organisms were determined by virulence tests. Antibiotic sensitivity 
testing was performed by the Kirby-Bauer’s disc diffusion method as per CLSI 
guidelines 2014(M100-S24). Detection of ESBL’s were done by phenotypic 
confirmatory test, MIC and ESBL gene by PCR.                                                                   
RESULTS 
             The prevalence of asymptomatic bacteriuria in pregnant women was 11.8%, 
more in the 21-30 years, primigravida and first trimester. Escherichia coli was the 
common isolate 54(45.76%) with Haemolysin18(33.33%) as the major virulence 
factor.  MRSA was not detected. Enterobacteriaceae showed 100% sensitivity to 
imipenem and piperacillin/tazobactam. Sensitivity to Cefotaxime and ceftazidime was 
92.6% for Escherichia coli, 89.5% for Klebsiella pneumoniae. 
Among Enterobactericeae, 6 were ESBL producers by phenotypic confirmatory 
test. Out of 6, 3(50%) were positive for CTX-M gene. 9 Escherichia coli isolates were 
positive for Mannose resistant haemagglutination and pap A gene. 
 CONCLUSION 
                   Asymptomatic bacteriuria in pregnant women which if not treated, might 
lead to various perinatal complications. Therefore, routine urine culture should be 
done for all antenatal women, to detect asymptomatic bacteriuria, and every positive 
case should be treated. 
Keywords: Asymptomatic bacteriuria, Pregnancy, Escherichia coli, Virulence factors, 
ESBL. 
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INTRODUCTION 
              Urinary tract infections (UTI) are one of the most prevalent bacterial 
infections and the significant cause of morbidity and mortality
1,2,3
. Urinary tract 
infection is next to respiratory tract infection, particularly in females
4
. Urinary tract 
infection is mainly a disease of the females, due to the anatomical structure of the 
female urethra
1
. 
            Of all uncomplicated urinary tract infections, Escherichia coli are responsible 
for 50%-90% of infections. They are mainly from faecal flora that can colonise the 
periurethral region, defeat the local host defences, enters and grow within the urinary 
tract
1
. The other bacterial pathogens that cause Urinary Tract infection are Klebsiella 
pneumoniae, Proteus species, Enterobacter species, Staphylococcus saprophyticus and 
Streptococcus agalactiae
5
. In pregnancy, urinary tract infections commonly occur, 
because of the physiological and morphological changes that occur in the 
genitourinary tract
6
.  
          There are 2 types of urinary tract infection (UTI). They are asymptomatic and 
symptomatic urinary tract infection
6, 7, 8
.  The definition of asymptomatic bacteriuria is 
the occurrence of actively multiplying bacteria, more than 10
5
 bacteria per ml of urine 
inside the urinary tract, exclusive of the distal urethra at a time when the patient has 
nil symptoms of UTI
9, 10
. Asymptomatic bacteriuria is frequent in women and more in 
occurrence with age, sexual activity. This is because of the short urethra, antenatal 
period and faecal contamination of the urinary tract easily
11, 12
.  
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            Antenatal women are twice more frequently affected than the same aged non-
pregnant women due to urinary stasis which is because of the progesterone effect in 
antenatal period in addition to various physiological and structural changes that occur 
in pregnancy
10
. In pregnant women, the occurence of asymptomatic bacteriuria was 
found to be 2% to 10%
11, 12
.  
               Pregnancy increases the succession from asymptomatic bacteriuria to 
symptomatic bacteriuria which can cause acute pyelonephritis in 20 to 50% of cases 
and contributes to adverse perinatal outcomes like post partum hypertensive disease, 
urinary tract infections, anaemia, prematurity and increased fetal mortality rates if left 
untreated
6,13,14
. 
                  
Asymptomatic bacteriuria is a microbial diagnosis and depends on the isolation 
of bacteria which is specific and quantitatively significant in a specimen of urine that 
is collected properly from pregnant women without any signs and symptoms of UTI.  
Hence detection and early treatment decreases the incidence of obstetric complications 
like acute pyelonephritis and chronic kidney failure not only in mother but it also 
reduces the premature delivery and fetal death
6
. The gold standard screening test for 
asymptomatic bacteriuria is the urine culture
6, 11, 15
.  
                The relatively increased occurence of asymptomatic bacteriuria, the 
consequences faced by the antenatal women, the ability to avoid undesirable outcomes 
with the management justifies the testing of asymptomatic bacteriuria in pregnancy
6
.  
                     In different geographical regions, the frequency of the pathogen isolated 
and their antimicrobial resistance patterns can vary. Hence, the common etiological 
11 
 
agents of asymptomatic bacteriuria should be investigated and their antimicrobial 
resistance pattern to be made aware of 
6
. The strains of Escherichia coli causing 
urinary tract infection are not like the faecal isolates
1
.                         
                   The virulence factors like adhesions, toxins, gelatinase enzyme and the 
surface hydrophobicity have an influence on the pathogenicity of the organism. The 
occurence, expression of the virulence genes, the environmental conditions in the host 
determine the virulence of the individual strains in a given infection. The colonisation 
of the organisms and the tissue damage is because of these virulence factors
1
.                    
                  Uropathogenic Escherichia coli (UPEC) strains are mostly marked by the 
presence of certain virulence determinants. Uropathogenic Escherichia coli have 
chromosomal gene clusters on pathogenicity islands and they encode adhesins such as 
S pili, P pili and afimbrial adhesins and other virulence genes
16
. 
                   Antenatal women with asymptomatic bacteriuria are prone to develop 
postpartum urinary tract infection, acute pyelonephritis in later half of pregnancy, 
anemia, chronic kidney failure, babies of low birth weight, prematurity and perinatal 
death if not treated. The management of asymptomatic bacteriuria in pregnancy 
promptly reduces the occurence of all these complications
17
.    
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AIMS & OBJECTIVES  
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AIMS AND OBJECTIVES 
1. To isolate the bacterial pathogens causing asymptomatic bacteriuria in 
antenatal women. 
2. To find the virulence factors of the bacterial isolates.  
      3.  To determine the antibiotic sensitivity pattern of the isolates.  
      4.  To detect the Extended Spectrum Beta Lactamase (ESBL) producers              
           from Gram negative bacterial isolates. 
      5.  To find the prevalence of Methicillin Resistant Staphylococcus aureus      
           (MRSA). 
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REVIEW OF LITERATURE 
             Bacteriuria is a commonly used term and literally means “Bacteria in the 
urine”. Infections in the urinary tract are one of the most frequent of all infections. 
The presence of infected urine in the bladder depends on the quantification of the 
number of bacteria in the excreted urine. Significant bacteriuria is a term used to 
describe the number of bacteria in voided urine that is (10
5 
bacteria/ml). The presence 
of atleast 10
5
 bacteria/ml of urine, infection must be considered as a serious one
18
.  
            Kass in 1957 suggested that 100000 bacteria/ml of urine is significant 
bacteriuria. In real infections, in patients who have not taken any antibiotics 
previously, the number of bacteria is ≥ 10
5
/ ml of urine. So, a quantitative method is 
adopted for the culture of viable bacteria in the specimen
19
.  
             Among the clinical presentations of urinary tract infection, asymptomatic 
bacteriuria is also present. The definition for asymptomatic bacteriuria is actively, 
persistently growing bacteria in significant counts (10
5
 bacteria per ml of urine) 
without any obvious symptoms. Covert bacteriuria is the other name of it. The short 
urethra in females contributes to this. The antenatal women are twice more commonly 
affected than same aged non-pregnant women.  The progesterone effect in pregnancy 
leads to urinary stasis is the reason behind this increase in pregnant women. The 
anatomical changes that occur also contribute to it
10
. 
            In women, asymptomatic bacteriuria is frequent and it increases with age and 
sexual activity. The reasons are short urethra, absence of prostatic secretions and easy 
contamination of urinary tract with faecal flora in pregnancy
11
. 
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           In the antenatal period, various changes occur in the body of women. 
Mechanical and hormonal changes enhance the problem of stasis in the bladder and 
reflux from the bladder to the ureters. The changes are short urethra, problem in 
maintaining the hygiene because of the distended abdomen. All these enhance the 
occurence of urinary tract infections. The smooth muscle relaxations followed by 
ureteral dilatation in antenatal period facilitate the bacteria to move from the bladder 
to the kidneys
9
.   
           Asymptomatic bacteriuria occurs in 2-10% of antenatal women. The detection 
of asymptomatic bacteriuria in pregnancy is significant, as untreated asymptomatic 
bacteriuria can cause symptomatic infection in 25% of culture positive cases, post 
partum urinary tract infection, pregnancy induced hypertension, anaemia, acute 
pyelonephritis, preterm birth, low birth weight babies and death of the foetus
11
. 
             The gold standard technique for the screening of asymptomatic bacteriuria in 
antenatal period is the culture of urine. Escherichia coli is the most common infecting 
organism and accounts for 75-90% of bacteriuria in pregnancy. 25-30% of 
asymptomatic bacteriuria women progress to symptomatic urinary tract infection. 
Thus, early detection and treatment is important to prevent the complications both in 
mother and the baby
11
. 
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PREGNANCY INDUCED URINARY TRACT CHANGES
20,21
: 
             In pregnancy, significant changes occur in the structure and function of the 
urinary tract. The kidneys become larger, renal calyces and ureters dilate. Some 
dilatation occurs before 14 weeks and is because of the progesterone induced 
relaxation of the muscular layers. In mid-pregnancy, marked dilatation is obvious. 
This is because of ureteral compression, mainly on the right side. During pregnancy 
vesicoureteric reflux is also there. An enhanced risk of upper urinary infection is due 
to the consequence of these physiological changes. 
            Soon after conception functional hypertrophy becomes evident. The size of the 
glomeruli increases, whereas the number does not increase. Increase in the effective 
renal plasma flow and glomerular filtration is due to the pregnancy induced intra renal 
vasodilatation. The glomerular filtration rate is increased by 20%, than the non 
pregnant values by 12 weeks of gestation. The plasma flow increases by 40% and 
glomerular filtration increases by 65% thereby the concentrations of creatinine and 
urea decreases. Other changes include those involved in the maintainence of normal 
acid-base homeostasis, osmoregulation, and fluid and electrolyte retention. The 
increase in plasma volume occurs physiologically in antenatal period. This decreases 
the concentration of urine. Most antenatal women get glucosurea, which promotes the 
growth of bacteria in the urine. 
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THE NORMAL FLORA OF THE URINARY TRACT
22,23 
• Coagulase negative Staphylococci (excluding S.saprophyticus) 
• Non hemolytic and Viridans Streptococci 
• Lactobacilli 
• Non pathogenic Neisseria species 
• Diphtheroids (Corynebacterium species) 
• Anaerobic cocci 
• Anaerobic Gram negative bacilli 
• Propionibacterium species 
• Commensal Mycobacterium species 
• Commensal Mycoplasma species 
HISTORICAL BACKGROUND
 
               In 1957, Kass proposed the use of quantitative culture of urine for the testing 
of urinary tract infection. Asymptomatic patients with counts quantitative of ≥10
5 
(CFU)/ml of excreted urine had the similar organisms when isolated in paired 
specimens using urinary catheters
19
. 
              Several patient populations, who were asymptomatic clinically, had a positive 
urine culture. These included pregnant women, cases with urinary catheters insitu and 
individuals with urological abnormalities. Pyelonephritis was identified as a vital 
difficulty in antenatal women with asymptomatic bacteriuria
24
. 
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EPIDEMIOLOGY
 
                As per the Cochrane collaboration study, 2-10% of all pregnancies, 
contribute to asymptomatic bacteriuria
25
. In a study done at Chennai by Balamurugan 
et al the prevalence is found to be 13%
3
. In most of the developing countries, recent 
studies show same statistics. In a cohort study of 9734 antenatal women, 5.1% had 
asymptomatic bacteriuria, 7.4% were found to have a urinary tract infection followed 
by 1.3% acute cystitis and 1% acute pyelonephritis respectively. The occurence of 
pyelonephritis in pregnant women ranges from 0.5 to 2%. Second half of pregnancy is 
more risky for pyelonephritis. This is because of the rising mechanical compression of 
the distended uterus. 
            Socioeconomic status is important in determining the prevalence of 
asymptomatic bacteriuria. Associated risk factors are history of diabetes, urinary tract 
infections occurring recurrently and anatomical anomalies of the urinary tract.  The 
effects of host factors like age, parity, race, sickle cell disease are all less clear. 
           Asymptomatic bacteriuria plays a major role for symptomatic UTI. 
Asymptomatic bacteriuria if not treated 30% of pregnant women develop 
pyelonephritis when compared to 1.8% of non-bacteriuric controls
26
.
 
ETIOLOGIC AGENTS OF ASYMPTOMATIC BACTERIURIA
26, 27, 28 
                 The aetiologic agents of bacteriuria are the same in non-pregnant and 
pregnant women. Major commonest pathogen is Escherichia coli contributing to 70-
80%
26
. Escherichia coli strains isolated from asymptomatic bacteriuria women have 
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fewer virulence characteristics than those of symptomatic women. Other organisms 
like Klebsiella pneumoniae, Proteus mirabilis, coagulase-negative staphylococci, 
group B streptococci and Gardenella vaginalis are common as well
27
. Other organisms 
causing asymptomatic bacteriuria are Enterobacter species and Pseudomonas 
aeruginosa
28
. 
               Streptococcus agalactiae in urine has been associated with labour and 
neonatal complications. Significance of the presence of anaerobic and fastidious 
organisms in the urine of antenatal women is unknown
26
. 
PATHOPHYSIOLOGY 
                 The occurence of bacteriuria without symptoms in non pregnant and 
antenatal women are the same, but it is usually benign in nonpregnant women. 
Outflow obstruction of urine in pregnant women causes stasis and in turn leads to 
pyelonephritis which complicates the asymptomatic bacteriuria. Physiological changes 
of the urinary tract that occur in pregnancy promote the development of asymptomatic 
bacteriuria to pyelonephritis. Progesterone induced dilatation of the ureters and renal 
pelvis, dislodgement of the bladder into the abdomen and stasis of urine due to 
reduced ureteral and bladder tone is the reason behind
29
. In foetus, the effects of 
asymptomatic bacteriuria are premature labour, babies with low birth weight and 
death of the foetus
11
. 
                 Virulence factors in uropathogenic strains of Escherichia coli include 
toxins, fimbriae and adhesins that allow attachment to uroepithelial cells that inhibit 
bacteria from urinary lavage, allows tissue invasion, multiplication, invasive infection 
21 
 
and pyelonephritis in antenatal women subsequently. Adherence is the single most 
important marker associated with the progression to pyelonephritis
29
. 
                 The virulence factors of Staphylococcus aureus are capsular 
polysaccharides, peptidoglycan, teichoic acid, protein A, enzymes, hemolysins, toxins 
and super antigens. The virulence factors of Pseudomonas aeruginosa are alginate, 
pili, neuraminidase, lipopolysaccharide, exotoxin A, enterotoxin, exoenzyme S, 
phospholipase C, elastase, leukocidin and pyocyanins
30
. 
 PATHOGENESIS 
              Bacteria that originate in the large bowel most likely colonise the urinary 
tract transperineally. Escherichia coli cause 75-90% of bacteriuria in antenatal women. 
The pathogenic virulence of Escherichia coli which is not the most plentiful in faecal 
isolates derives a number of factors like resistance to vaginal acidity, adherence to 
cells, rapid division in urine and the production of chemicals which reduce ureteric 
peristalsis and inhibit phagocytosis. Other organisms responsible for urinary tract 
infection include Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas and 
coagulase-negative staphylococci. The interaction between infection and the host is an 
interesting area of research and much is discovered about the roles of bacterial 
adhesions, uro-epithelial receptors and induction of inflammatory responses
22
. 
                         Adherence of the organisms to epithelial cells is important for the 
colonization and infection of mucous membranes. The colonization of the urogenital 
epithelium with the bacteria of susceptible persons is related to the successful invasion 
of the urinary tract. Urine and serum antibodies play an important part in the 
22 
 
pathogenesis of UTI.  The adherence of bacteria to the uroepithelial cells is prevented 
by the urinary antibodies and thereby they resist UTI
31
. 
                Mostly the organisms enter into the bladder, via the urethra. An insitu 
catheter helps their invasion which colonizes in the periurethral area, vaginal region 
and ascends. Bacteria that cause infection in healthy women and in persons with 
complications express different virulence properties
32
. The low sensitivity of the 
bacteria to the anti microbial agents used is the major problem associated with 
infections caused by biofilm forming bacteria
33
.  
VIRULENCE FACTORS OF ORGANISMS 
Adhesins 
                Increased adherence to periurethral and vaginal area promotes colonization. 
Pyelonephritis causing isolates are virulent than cystitis causing isolates. Urinary 
isolates are more virulent than colonic isolates. The adhesins of uropathogenic 
Escherichia coli occur as filamentous surface organelles termed fimbriae or as 
nonfilamentous proteins of outer membrane
18
. 
P Fimbriae 
                  The adherence of Escherichia coli to the epithelial cell receptors having 
globoseries glycosphingolipid is related to the attachment of most strains causing 
renal infection and is not inhibited by mannose - Mannose-resistant (MR). P fimbriae 
are a part of the P blood group antigen complex found in human red blood cells. The 
globoseries glycosphingolipid receptors (gal-gal) are present throughout the urinary 
tract, mainly in the kidney
18
. 
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Type I Fimbriae
18, 32 
                 Mannose-sensitive hemagglutination is due to type I fimbriae found in 
many enterobacterial species and especially in many strains of Escherichia coli, 
commonly expressed by isolates from cystitis than by control isolates and 
pyelonephritis isolates. Pil, fim gene cluster and other nine genes code for the type I 
fimbriae, proteins of structure and regulation. Type I fimbriae undergo phase variation 
which is because of an invertible promoter. Liquid media promotes the production of 
fimbriae. Bladder colonizers are generally fimbriated than kidney isolates. Type I 
fimbriae gets attached to uroplakins, the major glycoprotein of the uroepithelial cells. 
Type I fimbriae provoke invasion of the urinary bladder epithelial cells and recurrent 
infections.The bacteria within the urothelial cell form biofilm within a polysaccharide.  
 
Other adhesins
18
: 
             In addition to type P and type I fimbriae, various other adhesins include S, G 
type 1 c, Dr fimbriae, and X and M adhesins with differing molecular binding 
specificities and serologic properties have been found on uropathogenic strains of 
Escherichia coli. The Dr hemagglutinin family has non fimbrial and fimbrial adhesins. 
Four genes (dra A, B, C, D) that encode for the structural proteins and adhesins of the 
fimbriae have been found. The adhesins attach to the Dr blood group antigen 
component of decay accelerating factor, which is widely present along the urinary 
24 
 
tract and cause cellular invasion. Dr positive Escherichia coli persist in renal 
infections and have a role in interstitial nephritis and chronic pyelonephritis. 
            Adherent bacteria persist in the urinary tract and have growth advantages and 
increased toxicity. Dr adhesin and the Type I pili have been linked together to bladder 
epithelial cell invasion and intracellular persistence by uropathogenic Escherichia coli. 
A positive correlation is there between the bacterial adhesion and the difficulty in 
eradicating organisms with short course antibiotic therapy. 
            Studies with other bacterial uropathogens like Klebsiella species and Proteus 
mirabilis have also demonstrated the importance of adherence in the pathogenesis of 
UTI. Staphylococcus aureus rarely causes cystitis and ascending pyelonephritis, 
whereas, Staphylococcus saprophyticus is a frequent reason for lower urinary tract 
infections. Staphylococcus saprophyticus adheres more significantly to uroepithelial 
cells than Staphylococcus epidermidis or Staphylococcus aureus isolates
18
.  
 
OTHER VIRULENCE FACTORS: 
            Motile bacteria go up in the ureter against the flow of urine. The endotoxins of 
Gram negative bacilli reduce the peristalsis in the ureter and add to the renal 
parenchymal inflammation by phagocytic cell activation. In Proteus species, the 
urease produced by the infective microorganisms has the ability to cause 
pyelonephritis. The capsular K antigen present in the bacteria protects it from 
phagocytosis. 
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          The hemolysin produced by most uropathogenic strains cause tissue invasion 
and renal tubular epithelial and parenchymal damage, making iron available to the 
invading Escherichia coli. The hemolysin gene is mostly located adjacent to genes 
encoding for serum resistance and sialic acid - specific (S) fimbriae
18
. Hemolysin 
provides Escherichia coli with selective advantage by releasing iron from lysed 
erythrocytes and increases the pathogenicity by destroying epithelial and phagocytic 
cells
34
. 
                In uropathogenic strains of Escherichia coli, aerobactin an iron scavenging 
protein (siderophore) is present in higher frequency. Because of the conditions in the 
bladder are iron poor, iron acquisitions systems are often found in uropathogenic 
Escherichia coli. Increased number of iron acquisition systems is present in 
uropathogenic Escherichia coli strains than the commensal and fecal strains, which 
reflects the iron limiting urinary tract environment
18
. 
               Biofilms consists of mass of bacteria attached to a surface and covered 
within an extracellular matrix. Changes in gene and protein expression, as well as 
metabolic activity contribute resistance to host mechanisms of clearance and 
antimicrobial therapy in biofilms
35
. 
Virulence genes 
                Genes that have been identified that encode for the virulence factors are hlya    
(hemolysin), cnf1 (cytotoxic necrotizing factor1), iutA (aerobactin receptor), fim H 
(Type 1 fimbriae adhesion), pap (p fimbriae), iroN (catecholate siderophore receptor), 
omp T (outer membrane protease T). Cytotoxic necrotizing factor 1(cnf) causes 
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urinary tract infection and prostatitis. Iron regulated gene homologue adhesions (Iha), 
an outer membrane protein encoded by iha are virulence factor for urinary tract 
infection. Escherichia coli strains causing asymptomatic bacteriuria appear to have 
lost their ability to express functional virulence associated genes
18, 36
. 
HOST DEFENCE OF THE URINARY TRACT
18
: 
1. Urine ( osmolality, Ph, organic acids ) 
2. Mucosa of the urinary tract (Bactericidal, peptides, cytokines) 
3. Urinary inhibitors to prevent bacterial adherence 
4. Urine flow and micturition 
• Tamm-Horsfall protein  
• Mucopolysaccharide of the bladder oligosaccharides 
•  Secretory immunoglobulin A 
•  Lactoferrin. 
5. Inflammation 
                   Polymorphonuclear neutrophils, cytokines. 
6. Immunity 
                    Humoral and cell mediated immunity 
7. Others 
                    Prostatic secretions 
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LAB DIAGNOSIS  
Sample collection
30 
              Clean catchment of midstream urine is the most commonly used technique to 
collect the urine sample to avoid the contamination. The initial flow washes away the 
contaminants whereas the midstream urine reflects the bacterial colonization of the 
bladder. Periurethral cleansing with water and soap without bactericidal activity is 
insisted to reduce the contamination in females as culture results are modified with 
antibacterial soap.  
              Midstream clean catch urine is the most commonly used technique for sample 
collection.  The periurethral area and the perineum should be first cleaned with two or 
three gauze pads, soaked in soapy water, using a back to forward motion.  Then the 
periurethral area and perineum should be rinsed with water or sterile saline. 
               The labia should be held apart during voiding, and the first few millilitres of 
urine should be passed into a bedpan or toilet to flush out the bacteria from the 
urethra. The midstream portion of urine should then be collected in a wide mouthed 
sterile container and covered with a tightly fitted lid
30
.      
Specimen transport 
              Urine sample is processed within 2-4 hours or should be refrigerated to 
maintain the bacterial density. Preservative advised is 1.8% Boric acid where 
specimen to be transported and refrigeration is not possible. Results after prolonged 
storage will alter the culture results
32
.  
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Examination of urine 
Macroscopic examination 
             Urine to be observed for altered colour, presence of turbidity and deposits
37
. 
Screening tests for presumptive diagnosis of significant bacteriuria 
Leukocyte esterase test and nitrite test
17 
             The presence of nitrite and leukocyte esterase was tested with colorimetric 
Combur-10 multireagent strips as per the manufacturer’s instructions. 
Pus cell count of the uncentrifuged urine
17 
               With Neubauer’s counting chamber pyuria was detected. Pus cell count of 
≥10 cells/µl of urine corresponds to an excretion rate of 4* 10
5
 pus cells in 1 hour 
which is significant. 
Gram staining of uncentrifuged urine
17 
               1 drop of urine that was not centrifuged was taken on a clean slide and Gram 
staining done and examined for 20 fields. Presence of more than or equal to one 
bacteria per examined field indicates ≥10
5
 CFU/ml of urine. 
Triphenyl Tetrazolium Chloride (TTC) test
4, 38
: 
               Only at an alkaline p
H
 reduction of Triphenyl tetrazolium chloride to a red 
precipitate of Triphenyl formazan occurs and this occurs during a urinary tract 
infection. 
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Catalase test
4, 38 
 
 To a 2 ml sample of urine a few drops of hydrogen peroxide was added. 
Presence of the catalase enzyme was evidenced by frothing. A positive result is also 
obtained in hematuria.
 
Griess nitrite test
39 
              The reagent consists of an acid solution of sulfanilic acid and alpha 
naphthylamine which undergoes diazotization with nitrites to form a red dye. Nearly 
all the bacteria which cause asymptomatic bacteriuria reduce the nitrate to nitrite. 
Glucose test paper
38 
              The bacteria causing the infection utilises the minute amounts of glucose 
present in normal urine.  
Dip slide culture method
19, 38
  
               The dip-slide is a small plastic tray carrying a layer of an appropriate agar 
culture medium. Agar coated slides are immersed in urine or even exposed to the 
stream of urine during voiding incubated at 37 degree celcius overnight and the 
growth estimated by colony counting or by colour change of indicators. 
Advantage 
          It is especially convenient for routine screening of large number of patients. 
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Disadvantage 
          It does not provide material for microscopical examination for the cellular 
content of the urine and when the bacterial count is high and when the growth of the 
dip-slide is confluent, it is difficult to judge whether the growth is pure or mixed. 
IMPORTANCE OF SCREENING 
          For asymptomatic bacteriuria screening, no clear cut idea in the literature is 
present as to the timing and frequency of screening. In a study involving 3254 
antenatal women in Sweden was examined for the risk of getting bacteriuria in 
pregnancy.  The risk of getting the bacteriuria in pregnancy augmented from 0.8% in 
the I trimester to 1.93% at the III trimester. The risk of getting the infection was the 
most between the 9
th
 and 17
th
 week. 16
th
 gestational week was the most favourable 
time for screening. Management at that time will provide the maximum benefit.           
As per many studies, the urine culture done once at first trimester is adequate, whereas 
few studies report that it must be done in all the three trimesters to enhance the 
sensitivity
26
.  
            Screening and treating the asymptomatic bacteriuria in antenatal women is 
important in obstetric care. Most of the pregnancy related guidelines add screening as 
a test for asymptomatic bacteriuria. Pyelonephritis has been prevented by the 
screening and management of asymptomatic bacteriuria and shown to be cost 
effective
25
.  
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Urine culture
40 
              A semi quantitative calibrated loop technique was used for the isolation of the 
organism. A loopful of urine that was uncentrifuged was inoculated on to the CLED 
and blood agar plates. The plates were incubated at 37
0
C for 18-24 hours aerobically. 
The colony forming units per ml of urine was calculated. By standard microbiological 
techniques, bacterial isolates were identified and then antibiotic sensitivity testing was 
done by Kirby Bauer’s disc diffusion method. 
 
COMPLICATIONS
41 
            Pregnant women with asymptomatic bacteriuria are prone to the risk of 
developing symptomatic UTI and acute pyelonephritis. Hill et al has reported an 
incidence of 1.4% of acute pyelonephritis in pregnant women. Smaill et al in a 
systematic review has shown the occurence of pyelonephritis in the untreated 
asymptomatic bacteriuria group to be 21% with a range of 2.5 to 36%.  Management 
of asymptomatic bacteriuria leads to a 75% fall in the incidence of pyelonephritis. 
Proper management of asymptomatic bacteriuria also decreases the symptomatic UTI 
by 80-90%.  The incidence of anemia was high in all the age groups despite treatment. 
The association between anaemia and asymptomatic bacteriuria could not be 
established because of the multipronged aetiopathogenesis of anemia in pregnancy.              
Asymptomatic bacteriuria in pregnancy is associated with IUGR, hypertensive 
disorders of pregnancy, Pre term labour, and low birth weight infants. All these 
complications emphasize the importance of early detection and management of 
asymptomatic bacteriuria. 
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 TREATMENT 
                Since no proper idea is found in the studies regarding the preference of 
antibiotic and its duration of therapy, more than the clinical trials the treatment 
depends on the national patterns of antibiotic practice and its resistance. The antibiotic 
of choice should have high efficacy, decreased resistance and good fetal and maternal 
safety
26
. Management of asymptomatic bacteriuria has been shown to prevent 
pyelonephritis, management with a suitable antimicrobial agent is recommended for 
all pregnant women with significant bacteriuria. The aim of the treatment is to 
maintain sterile urine throughout pregnancy and thereby prevent the complications
18
. 
                Treatment with a relatively non-toxic drug for 7 days eliminates bacteriuria 
in 70-80% of antenatal women. The relatively safe drugs in pregnancy are a 
sulphonamide, amoxicillin, cephalexin, amoxicillin-clavulanate and nitrofurantoin.  
Quinolones and tetracyclines must be avoided in pregnancy. Sulphonamides should 
not be given in the last few weeks of pregnancy because they cause 
hyperbilirubinemia and kernicterus in the newborn baby
18
. Nitrofurantoin has a good 
sensitivity (90.98%), against both ESBL and non ESBL producers. The absorption of 
nitrofurantoin when taken orally is 40-50% and so, it is taken with food.  The drug has 
few adverse effects. It can be used safely for the management of uncomplicated 
cystitis in pregnancy
42, 43
.  
             Urine cultures should be done 1 to 2 weeks after stopping the therapy and at 
regular intervals like monthly for the remaining gestational weeks. If bacteriuria 
recurs, treatment should be given for reinfection or relapse.  Using catheters should be 
avoided during delivery
18
.   
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Antibiotics commonly used for asymptomatic lower urinary tract infections
26
 
DRUG ADVANTAGES DISADVANTAGES 
Cephalexin No tetatogenicity. Penicillins and 
cephalosporins are 
associated with allergic 
manifestations 
occasionally. 
Nitrofurantoin Appears safe in all 
trimesters of pregnancy. 
Not useful in 
pyelonephritis because 
therapeutic levels are 
achieved only in the urine. 
Not beneficial against 
Proteus species. 
Trimethoprim-
sulfamethoxazole 
              -- In first trimester, can cause 
neural tube and birth 
defects. Sulphonamides are 
avoided in III trimester to 
prevent neonatal toxicity.  
 
 
 
34 
 
 
BACTERIAL RESISTANCE
44
: 
Resistance of microorganisms to drugs involve many mechanisms which are as 
follows 
1. Certain microorganisms produce enzymes which destroy active drug. For ex.   
β lactamases produced by Staphylococci and Gram negative organisms. 
2. Some of them change their permeability to the drug. 
3. Developing an altered target for the drug or changed metabolic pathway which 
bypasses the reaction repressed by the drug. 
      4.  Production of an altered enzyme that can perform its metabolic activity but 
very little action is altered by the drug.  
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS
30
  
             Staphylococcus aureus is an important human pathogen present in the 
surroundings and in the anterior nostrils of 20- 40% of adults. It is also seen in the 
axillae; intertriginous skin folds, the perineum, and the vagina. It is responsible for 
mild to severe life threatening infections including skin and soft tissue infections. 
Originally, penicillin was the treatment of choice for the management of serious 
Staphylococcus aureus infections. The advent of penicillin resistance in the 
Staphylococcus aureus was due to the acquisition of plasmid borne genetic elements 
coding for β lactamase production.  
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MECHANISM OF RESISTANCE 
The chromosomally localized mecA gene is responsible for methicillin 
resistance. Penicillin binding protein 2a synthesis requires mecA gene. Penicillin 
binding protein is membrane bound enzyme which catalyses the transpeptidation 
effect which is responsible for cross linking of peptidoglycan chains. All beta lactam 
antibiotics have low affinity for PBP2a. It substitutes other PBPs which enables 
Staphylococcus to survive exposure to high concentration of beta lactam antibiotics
30
. 
Four different SCCmec elements have been recognized. SCCmec type I, II and 
III is associated with Health care associated MRSA (HA-MRSA). Community 
associated MRSA tend to carry Type IV element. CA - MRSA has a characteristic 
antibiotic susceptibility pattern, carries specific virulence factor such as Panton –
valentine leukocidin and specific SCC mec type IV
45, 46
. 
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BETA LACTAMASES 
BETA LACTAM ANTIBIOTICS 
Beta lactam antibiotics are the ones which contain β lactam ring in its structure. 
It includes Penicillins, Cephalosporins, Monobactams and Carbapenem
30
. 
MECHANISM OF ACTION
47, 48 
       All beta lactam antibiotics inhibit the bacterial cell wall synthesis. The bacteria 
produce UDP - N – acetylmuramic acid, UDP – N – acetyl glucosamine. The 
peptidoglycan synthesis residues are linked together forming lengthy strands and the 
UDP is cut off. Terminal D alanine of the peptide chain is cleaved by the 
transpeptidases. The cross linking is necessary for the strength and rigidity of the cell 
wall. The beta lactam antibiotics inhibit the transpeptidases so that cross linking does 
not take place. 
BETALACTAMASES 
This is a heterogeneous group of penicillin recognizing proteins. They belong 
to members of super family of active site serine protease. These enzymes inactivate β 
lactam antibiotics
30
.   
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CLASSIFICATION OF BETA LACTAMASES
49
 
Schemes of functional classification that were accepted by β-lactamase 
researchers include: 
(i)  In 1968, Cephalosporinases and penicillinases were grouped on the basis of 
reaction to specific antibody (Sawai et al
50
).  
(ii) In 1973, the Richmond and Sykes scheme classified the enzymes into five main 
divisions based on the gene coding for β-lactamase and the substrate profile. 
(iii)  In 1989, Bush scheme classified β-lactamase on the basis of molecular 
structure and the substrate inhibition. 
(iv)  In 1980, Ambler was the first to propose the Molecular structure 
classifications. 
(v)    More recently, Bush, Jacoby, and Medeiros devised a classification scheme         
based on the sequence of nucleotide on the genes for placing β-lactamases 
into functional groups and on the enzyme’s biochemical properties and 
molecular structure. 
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CLASSIFICATION OF BETA LACTAMASES
49 
 
(Classification schemes for bacterial β-lactamases) 
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Representative enzyme 
CAb EDTA 
1 1 
Ia,Ib,Id Csasea C 
Cephalosporins 
- - 
AmpC from Gram negative bacteria, 
MIR-1 
2a 2a 
not 
included 
Pcase V A 
Penicillin  
+ - 
Penicillinases from Gram Positive 
bacteria 
2b 2b 
III Pcase I A 
Penicillins, 
Cephalosporins + - TEM-1, TEM-2, SHV-1 
2be 2b' 
not 
included 
except K1 
in class IV 
Cxase A 
Penicillins, Narrow 
spectrum and 
extended spectrum 
Cephalosporins, 
Monobactams. + - 
TEM-3 to TEM-26, SHV-2 
to SHV-6, Klebsiella oxytoca 
K1 
2br 
not 
inclu
ded 
not 
included 
not included A 
Penicillins 
± - TEM-30 to TEM-36, TRC-1 
2c 2c 
II,V Pcase IV A 
Penicillins,Carbenicil
lins + - PSE-1, PSE-3, PSE-4 
2d 2d 
V 
Pcase II, 
Pcase III 
D 
Penicillins, 
Cloxacillin ± - 
OXA-1 to OXA-11, PSE-2 
(OXA-10) 
2e 2e 
1c Cxase A 
Cephalosporins 
+ - 
Inducible cephalosporinases 
from Proteus vulgaris 
2f 
not 
inclu
ded 
not 
included 
not included A 
Penicillins, 
Cephalosporins, 
Carbapenems + - 
NMC-A from Enterobacter 
cloacae, Sme-1 from Serratia 
marcescens 
3 3 
not 
included 
not included B 
Most β lactams, 
including 
carbapenems - + 
L1 from Xanthomonas maltophilia 
CcrA from Bacteroides 
fragilis 
4 4 
not 
included 
not included NDc 
Penicillins 
- 
Penicillinase from Pseudomonas 
cepacia 
 
a Csase, cephalosporinase; PCase, penicillinase; CXase, cefuroxime-hydrolyzing  
 
           β-lactamase. 
 
b         CA, clavulanic acid. 
 
c        ND, not determined. 
 
39 
 
DETECTION OF BETA LACTAMASES
19,30
 
Biochemical tests are used to detect β lactamases. β lactamases hydrolyses 
benzyl pencillin to produce penicilloic acid which was measured. This acid production 
was measured by 
1. Acidometric method: change in pH of an indicator dye is measured. 
2. Iodometric method:  
3. Chromogenic cephalosporin method: 
Normally Nitrocefin is yellow in colour which turns red on production of β-
lactamases. 
β LACTAMASE INHIBITORS
30
 
Beta lactamase inhibitors are enzymes that are similar to β lactam antibiotics. 
They bind either reversibly or irreversibly to beta lactamase, thereby preventing β 
lactam antibiotics from destruction. They act as suicide bombers, utilizing all 
available enzymes. Clavulanic acid, Sulbactam and Tazobactam are some of the 
examples of beta lactamase inhibitors that have gained importance in clinical 
medicine. 
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EXTENDED SPECTRUM BETA LACTAMASES (ESBL) 
THE OCCURRENCE OF ESBLS 
ESBLs are β-lactamases that belong to Ambler class A. They have the ability to 
produce resistance to the I generation cephalosporin, II generation cephalosporin and 
III generation cephalosporin, penicillins and aztreonam (but not the carbapenems or 
cephamycins). These antibiotics are hydrolysed by these enzymes. β-lactamase 
inhibitors like clavulanic acid inhibit these enzymes
51
 and placed under Bush’s 
classification 2be
52
.  
ESBL’s are first reported in Germany in 1983 followed by France in 1985 
among Klebsiella spp. ESBL occurs in every part of the world and in most genera of 
enterobacteriaceae
51
. Generally, ESBLs are β-lactamases which are mediated by the 
plasmids. They are present most frequently in Escherichia coli, Klebsiella 
pneumoniae, Proteus mirabilis and other Gram negative bacilli
53
. There are more than 
200 different ESBLs reported
52
. 
EXTENDED SPECTRUM BETA LACTAMASES - DETECTION METHODS     
SCREENING OF ESBL  
Disc Diffusion method
51, 53, 54
 
     The disc diffusion methods are the screening test for ESBL production by 
Escherichia coli, Klebsiella species, and Proteus mirabilis as proposed by CLSI 2014. 
Laboratories use cefotaxime, ceftazidime, cefpodoxime, ceftriaxone and aztreonam 
for the screening of ESBL production. More than one of these antibiotics should be 
41 
 
used to improve the sensitivity of the detection. If the screening test is positive, it 
should be confirmed by phenotypic confirmatory test. 
CLSI Recommendations for ESBL Detection
54 
Drugs(cephalosporins) 
CLSI (M100-S24) recommended 
Zone diameter(sensitive) 
Cefotaxime ≥27mm 
Ceftriaxone ≥25mm 
Ceftazidime ≥22mm 
Cefpodoxime ≥17mm 
Aztreonam ≥27mm 
 
III. ESBL Detection methods recommended by Clinical Laboratory Standard 
Institute (CLSI) 
54
. 
Phenotypic confirmatory test / Disc Potentiation Test
51, 53, 54
. 
 
The CLSI advocates the phenotypic confirmatory test for the detection of 
production of ESBL by Klebsiella and Escherichia coli which use the cefotaxime or 
ceftazidime discs (30µg) with or without clavulanate (10µg). Confluent growth of test 
organism on Mueller Hinton agar shows difference of 5mm along the cephalosporin 
with clavulanate disc compared to cephalosporin disc alone. 
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Double disc synergy test
53,54
 
        In Mueller – Hinton agar plate a lawn culture of the test organism is done on 
which third generation cephalosporin disc (Ceftazidime, Cefotaxime or Ceftriaxone) 
and Augmentin are placed 30 mm apart. When zone of inhibition of cephalosporin 
extends towards Amoxycillin/clavulanate disc, it is taken as positive for production of 
ESBL. 
1. Broth Micro dilution
51
 
             Disc potentiation test can be done using broth microdilution assays by using 
ceftazidime (0.25 to128µg/ml), ceftazidime with clavulanate (0.25/4 to128/4 µg/ml), 
cefotaxime (0.25 to 64µg/ml) and cefotaxime / clavulanate (0.25/4 to 64/4 µg/ml) 
decrease in MIC of two fold serial dilution of cephalosporin with clavulanate 
compared to the MIC of cephalosporin alone suggests positive for ESBL production. 
 
COMMERCIAL METHODS AVAILABLE TO DETECT ESBL  
Epsilometer-Test for ESBLs
55,56
 
        Drug impregnated plastic strips are used in which one end contains a gradient of 
ceftazidime (0.5µg - 32µg/ml) and ceftazidime plus clavulanic acid (0.064-4µg/ml) in 
a different concentration gradient on the other side, along with a predetermined 
concentration of clavulanic acid (4µg/ml). The manufacturer recommends about eight 
– fold reduction in MIC when combined with clavulanate as positive. The sensitivity 
of this method is reported as 87-100% and the specificity as 100%. 
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(ii)  Vitek ESBL
56,57
  
            Vitek ESBL cards contain cefotaxime and ceftazidime alone and 
cephalosporin plus constant concentration of clavulanate. Cards are inoculated in 
the same manner as that for regular vitek cards. Cards are analysed automatically 
as soon as the growth in the control well has attained a set threshold. A prefixed 
decrease in the growth of cefotaxime and ceftazidime plus clavulanic acid wells is 
compared with the growth in the wells having cefotaxime/ceftazidime alone, 
indicates positive for ESBL producer. The sensitivity and specificity of the test is 
more than 90%. 
 Molecular ESBL detection techniques 
Test Advantages Disadvantages 
DNA Probes  Gene family specific (e.g., 
TEM or SHV) 
Labour intensive, cannot 
differentiate between ESBLs 
and non ESBLs, and variants of  
TEM or SHV 
Polymerase 
chain reaction 
Easier in performing, gene 
family specific(e.g.,TEM or 
SHV) 
cannot distinguish between non 
ESBLs and ESBLs, and  
variants of TEM or SHV 
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Test Advantages Disadvantages 
Oligotyping Detects specific TEM 
variants 
Requires oligonucleotide 
probes that are specific, 
labourious, not able to detect 
new variants. 
PCR- RFLP Easy to perform, specific 
nucleotide changes can be 
detected.  
Nucleotide changes must result 
in altered restriction site for 
detection. 
PCR- SSCP Can distinguish between 
many of SHV variants 
Requires special electrophoresis 
conditions. 
Nucleotide 
sequencing 
 All variants can be 
detected, gold standard. 
Labourious, difficult 
technically and to interpret 
manually. 
Real Time 
PCR 
Rapid identification, 
minimum cross 
contamination 
Expensive, technical skill 
required 
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MATERIALS AND METHODS 
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MATERIALS AND METHODS 
                This cross sectional study was done for one year and six months from 
January 2014 to June 2015 to study the bacterial isolates causing asymptomatic 
bacteriuria in pregnancy at Government Kilpauk Medical College and Hospital, 
Chennai. Totally 1000 urine samples were collected from 18-40 years of age group 
among pregnant women and were studied during this period. 
INCLUSION CRITERIA 
1. All antenatal women without signs and symptoms of infection in the urinary 
tract.  
EXCLUSION CRITERIA 
1. Antenatal women who took antibiotics in the past two weeks. 
2. Antenatal women with signs and symptoms of infection in the urinary tract. 
3. Structural and functional abnormality of the urinary tract. 
SAMPLE COLLECTION
6 
            A total number of 1000 antenatal women who attended antenatal clinic at 
Government Kilpauk Medical College and Hospital were included in the study. From 
the asymptomatic antenatal women, urine specimens were collected by mid-stream 
clean catch method in a sterile container, which is wide mouthed and covered with 
tight fitting lids after obtaining informed consent. 
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SPECIMEN TRANSPORT  
Specimens were transported immediately to the microbiology laboratory and 
processed without delay. 
SAMPLE PROCESSING
37, 58 
Macroscopic examination 
              Colour, turbidity and deposits of the urine samples were observed 
macroscopically and the results were recorded
37, 58
. 
               The collected mid stream clean catch urine sample was divided into two 
portions. One half was taken for urine microscopy and culture and the other half was 
used for commercial reagent strip test for the nitrite and leucocyte esterase.  The 
presence of nitrite and leucocyte esterase is noted by specific colour change in the 
panel provided by the manufacturer. The samples were tested as per the 
manufacturer’s instructions. The results were compared with the colour code on the 
reagent strip container between 30 and 60 seconds as per the instruction manual. The 
positive results were recorded
59
. 
Microscopic examination 
1. PUS CELL COUNT OF THE UNCENTRIFUGED URINE
60
 
  Presence of polymorphonuclear neutrophils (PMNs) was detected by urine 
wet mount examination. Microscopic analysis was done with 0.05 ml of the 
uncentrifuged urine.  
          ≥ 5 pus cells/high power field       -        positive finding.  
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2. GRAM STAIN OF UNCENTRIFUGED URINE
37,61
: 
               One drop of uncentrifuged urine was smeared on a grease free glass slide. It 
was air dried, heat fixed, Gram stained and seen under oil immersion objective. 
Significant bacteriuria correlates with the presence of atleast 1 organism / oil 
immersion field on examining 20 fields. 
URINE CULTURE 
Semi-quantitative method
37, 40, 61 
            To isolate the organism, a semi-quantitative calibrated loop technique was 
used. One loopful of properly mixed urine that was not centrifuged was inoculated 
onto the surface of Nutrient agar, 5% sheep Blood agar, Mac Conkey agar and 
Cysteine Lactose Electrolyte Deficient agar using a calibrated loop that delivers 0.01 
ml of urine sample.  The culture plates were incubated under aerobic conditions at 37
0 
C for 18-24 hours. The colonies were counted using colony counter and the number of 
colony forming units were multiplied by 100 to find out the number of 
microorganisms present per millilitre of urine.   
         ≥ 10
5 
colony forming units/ml     -     significant bacteriuria.                            
 The diagnostic criteria for asymptomatic bacteriuria was considered when atleast two 
consecutive urine samples showed more than or equal to 10
5
 colony forming units in 
1ml of urine of the single species without any UTI symptoms
62
. To differentiate 
pathogens from commensals, standard microbiological methods were followed. The 
importance of the isolates were identified based on presence of pus cells in direct 
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Gram staining, pure growth and colony morphology on culture plates and biochemical 
reactions by using standard microbiological techniques.  
VIRULENCE FACTORS OF VARIOUS ORGANISMS 
VIRULENCE FACTORS OF ESCHERICHIA COLI 
Haemolysin - Plate haemolysis test
63
: 
              The alpha haemolysin production by Escherichia coli was tested by the plate 
haemolysis test.  On 5% sheep blood, the bacteria was inoculated and incubated at 
35°C overnight. A zone of lysis of the red blood cells around the colony and clearing 
of the medium indicates haemolysin production.  
               The hemolysin detection was done for various other organisms like Proteus 
mirabilis, Pseudomonas aeruginosa, Staphylococcus aureus and Enterococcus faecalis. 
The gelatinase test
19
: 
Using gelatin agar, the gelatinase production was tested. The organism was 
inoculated on to the plate and kept for incubation at 37° C aerobically for 24 hours.  
1% tannic acid solution was poured over the colonies. The test was considered 
positive if there was a development of opacity around the gelatin liquefying colonies, 
quick to develop but fades as the medium also becomes opaque.  
Cell surface hydrophobicity
63 
Salt aggregation test (SAT) was used to determine the cell surface 
hydrophobicity of Escherichia coli. Using phosphate buffer a bacterial suspension was 
prepared. 10µL of the suspension and 10 µL of ammonium sulphate solution of 
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differing molarity, i.e., from 0.3125 M through 5 M was mixed on a glass slide and 
rotated for 1 minute and observed.  
Salt aggregation test was considered positive if there was visible clumping in 
highest dilution.  
Auto Aggregative Strains – Clumping in 0.002 M phosphate buffer alone. 
Escherichia coli strains which had a Salt Aggregation Test value of ≤ 1.25 M were taken 
as cell surface hydrophobicity positive. 
Serum resistance
63 
Overnight cultures of Escherichia coli grown on blood agar at 37°C were taken 
and mixed in Hank’s balanced salt solution (HBSS). Fresh human serum (0.05 ml) 
and (0.05 ml) of bacterial suspension was mixed and incubated at 37° C for 3 hours. 
10µL of samples were then inoculated on blood agar plates and incubated for 18 hours 
at 37° C and viable count calculated. The percentage of bacteria viable after 3 hours of 
incubation indicates the resistance of bacteria to serum bactericidal activity. 
   Serum sensitive:    viable count decreased to 1% of previous value. 
   Serum resistant:    viable count more than 90% of organisms survived     
                                 after 3 hours. 
Haemagglutination test
64 
             The test strain was taken from the Nutrient agar plate to peptone water (pH 
7.0) and grown at 37
0
C for 24 hours. Human‘O‘erythrocytes were taken in Alsever 
solution and were washed two times with phosphate buffered saline (PBS) and 3% 
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suspension was made in the same buffer. One drop of bacterial culture and one drop of 
erythrocyte suspension were carefully mixed on a slide. The slide was rotated for 1 
minute at room temperature and the presence and absence of macroscopic 
haemagglutination was seen. To test the effect on haemagglutination by D-mannose, 1 
drop of mannose solution (25mg/ml of PBS; Ph 6.8) was added prior to the addition of 
red blood cell suspension and any difference in the degree of haemagglutination was 
noted.    
BIOFILM DETECTION BY MICROTITRE PLATE METHOD
65
 
             From fresh agar plates the organisms were taken and inoculated into Brain 
Heart Infusion Broth with 2% sucrose and kept in the incubator at 37
0 
C for 24 hours. 
With fresh medium, broth was diluted to 1: 100. 200 microlitres of the diluted cultures 
were inoculated into a sterile 96 well flat bottomed culture plate made of polystyrene. 
Medium without culture was used as control to look for the sterility and the non 
specific binding of the media. At 37
0 
C, the microtitre plate was kept in the incubator 
for 24 hours. 
           At the end of incubation the plates were tapped to remove the contents of each 
well. The wells were then washed with 200 µl of phosphate buffer saline for 4 times to 
eradicate the planktonic bacteria. Biofilms produced by sessile adherent bacteria in 
plate were stained with 0.1% crystal violet for one minute after fixing with 2% sodium 
acetate. Excess stain was washed thoroughly with water without any ions and the plate 
was dried in air. Adherent organisms which produced biofilm on all side of the wells 
were evenly stained with crystal violet. 
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            Optical density (OD) of adherent bacteria was determined with a micro ELISA 
auto reader at 570 nm wavelength. These OD values represent the bacteria strongly 
attached to surface and biofilm producing.  Experiment was done in triplicate and the 
values were then averaged and standard deviation (SD) was calculated.  The average 
OD value of the media control well was subtracted from all the test values. 
Classification of bacteria adherence:  
The reading values are interpreted as follows 
Sample OD Value Biofilm Formation 
Sample OD  > 0.24 Strong biofilm producers 
Sample OD values between 0.12-0.24 Moderate biofilm producers 
Sample OD < 0.12 Non/weak biofilm producers. 
 
The biofilm detection was done for various other organisms like Klebsiella 
pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus aureus and 
Enterococcus faecalis. 
MANNOSE RESISTANT HAEMAGGLUTINATION GENE DETECTION BY 
POLYMERASE CHAIN REACTION (PCR)
 16, 66, 67
  
Methods for DNA Extraction: 
         DNA extraction was performed with DNA purification kit and by using 
Polymerase chain reaction master mix. 
 Master Mix 2X has 2U of Taq DNA polymerase, 10X Taq reaction buffer, 2mM 
Magnesium chloride and 1µl of 10mM dNTPs mix, Polymerase Chain Reaction 
additives. For performing gel electrophoresis the following were used. 
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 Agarose,  50X TAE buffer,  6X gel loading buffer, Ethidium bromide. 
 DNA extraction Procedure: 
The overnight culture of the Escherichia coli in nutrient broth was taken in an 
amount of 1.5 ml.  It was then centrifuged for 5 minutes at 6000 rotations per minute.  
Then the sediment was taken as the pellet. 
• In 200µl of Phosphate Buffer Saline (PBS) pellet was suspended. 
• 180µl of lysozyme Digestion Buffer was mixed to 20 microlitre of lysozyme 
and incubated at 37°C for 15 minutes. 
• 200 microliters of Lysis buffer was mixed gently with 20µl of Proteinase K 
[10mg/ml] and incubated in a water bath at 56°C for ten minutes 
• 300 microlitre of isopropanol was added and mixed well. 
• Whole lysate was transferred into Pure Fast spin column. It was then 
centrifuged for one minute at 10000 rpm. 
• Discard flow through and 500µl of Wash Buffer-1 was added and centrifuged 
at 10000 rpm for 1Minute.  
• Discard flow through and 500µl of Wash Buffer-2 was added and centrifuged 
at10000 rpm for 1minute. This procedure was done for two times. 
• Discard flow through centrifuged column for 2 more minutes so that any 
residual ethanol will be removed.   
• 100µl of Elution Buffer was added to elute the DNA, and centrifuged for one 
minute. 
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Extracted DNA Quality and Quantity was verified by loading in 1% agarose gel with 
10µL of DNA extracted.  
Primer 
 Pap A-145bp 
 Forward Primer: 5’- GGCGCTGACAGAAGGTGCCATT- 3’ 
 Reverse Primer: 5’- CATGCCCAGTTCCCGGCCTTTT- 3’ 
 PCR Product size: 145bp  
Procedure for running PCR: 
[25µl of Master Mix: 10X Taq buffer, 2mM Magnesium chloride, 0.4mM dNTPs mix, 
and 2U Proofreading Taq DNA polymerase] 
1. Reactions were set up as; 
Components/Quantity 
Master Mix in PCR vial -10µl 
Primer Mix (10pmoles/µl) - 5µl 
Genomic DNA - 5µl 
Total amount - 20µl 
2. All these were mixed gently and spinned down briefly. 
3. They were then placed in the PCR machine and programmed; 
Initial Denaturation: 94ºC for 5 minutes 
Denaturation: 94ºC for 30seconds in cycles of 35 
Annealing: 58ºC for 30 seconds in cycles of 35 
Extension: 72ºC for 30 seconds in cycles of 35                  
Final extension: 72º C for 5 minutes 
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Loading: 
1.  Agarose gel 2% was made. [In 100ml of 1x TAE buffer 2gm of agarose was 
mixed] 
2. 8µl 6X Gel loading dye was taken in each PCR vial and 15µl of polymerase 
chain reaction sample was loaded. 
3. At 50V, electrophoresis was run till the dye reaches 3/4th distance and the 
bands were seen in UV Transilluminator. 
 
 Method to perform Agarose gel electrophoresis: 
• 2gm agarose was mixed in 100ml of 1X TAE buffer; it was melted by heating 
in a micro oven. 
• When the temperature of agarose gel was about 60ºC, Ethidium bromide (5µl) 
was added. 
• Into the gel platform warm agarose solution was added slowly. 
• Till the agarose got solidified it was kept undisturbed. 
• Into the submarine gel tank1XTAE buffer was added.  
•  Gel platform was kept into tank without any disturbance. The tank buffer level 
was kept maintaining upto 0.5cm above the gel. 
• Polymerase Chain Reaction samples were loaded after mixing with gel loading 
dye and 10µl HELINI 100bp DNA Ladder. 
• Electrophoresis was done at 50V till the dye reaches 3/4th distance of the 
agarose gel. The Agarose gel was seen with UV Transilluminator, the pattern 
of the bands were seen and interpreted.  
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VIRULENCE FACTORS FOR KLEBSIELLA PNEUMONIAE:   
Demonstration of Capsule
19
: 
A large loopful of undiluted India ink was taken on a slide and a small amount 
of solid bacterial culture was emulsified.  A clean, grit free coverslip was placed on 
the slide. The capsule was seen as a clear zone surrounding the microorganism on the 
brown-black ground.  
VIRULENCE FACTORS FOR PROTEUS MIRABILIS
33, 68 
          The virulence factors of Proteus mirabilis were done by hemolysin detection, 
serum resistance, mannose resistant haemagglutination and biofilm detection.  
VIRULENCE FACTORS OF PSEUDOMONAS AERUGINOSA
 
Virulence factors of Pseudomonas aeruginosa was determined by β-hemolysin 
detection
30
, pyocyanin pigment seen in Nutrient agar plate
69, 70
 and biofilm detection. 
VIRULENCE TESTS FOR STAPHYLOCOCCUS AUREUS    
Slide coagulase test
30 
A colony of the test organism was emulsified with saline on a microscopic 
glass slide. Similar suspensions of positive and negative control strains were used. 
One drop of undiluted plasma was mixed to the test suspension on the slide and mixed 
with the sterile applicator stick. The slide was rocked back and forth. A coarse 
clumping of the organism visible to the naked eye within 10 seconds was taken as 
positive.  
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Tube coagulase test
19
 
A 1-in-6 dilution of the plasma in 0.85% NaCl was taken and 1 ml volumes of 
it were taken in small tubes. A colony of the suspected organism was emulsified in a 
tube of the diluted plasma. With each batch of tests, tubes with known coagulase 
positive and coagulase negative cultures were used as controls. A tube of unseeded 
diluted plasma was also used to check that the plasma does not clot spontaneously.The 
tubes were kept in a water-bath at 37
0
C for 4 hours and were examined at 1, 2 and 4 
hours for clot formation by slanting the tube through 90 degrees. Any degree of clot 
formation was taken as positive. 
Urease production
19
  
Christensen’s urea slopes were used. The slope was inoculated heavily with the 
organism over the entire slope surface and incubated at 37
0
C. The slope was examined 
after 4 hours and after overnight incubation. The slopes were considered as urease 
positive if the colour changed to purple-pink.    
DNase test
19 
The test was done using DNase agar. On the DNase agar spot inoculation of the  
test organism were done and incubated at 37
0
C for 18-24 hours aerobically. The plate  
was then flooded with a few ml of 1 mol/litre (3.6%) hydrochloric acid. Unhydrolysed  
DNA was precipitated and which produced a white opacity or cloudiness in the agar  
was considered as positive. 
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Phosphatase test
19 
  1% aqueous solution of sodium phenolphthalein diphosphate was prepared 
and 10 ml of it was added to 1000 ml of melted Nutrient agar cooled to 50
0
C and the 
plates were poured.  On this medium, the test organism was grown overnight at 37
0
C.  
The plate was inverted and a few drops of ammonia solution SG 0.88 were added. The 
colonies which turned bright pink within a few minutes were considered as positive. 
VIRULENCE FACTORS OF ENTEROCOCCI
71
  
The virulence factors of enterococci were the gelatinase, β-hemolysin and the 
biofilm production. 
Gelatinase test
71 
          Enterococus isolates were inoculated onto peptone yeast extract agar having 
gelatin (30g/L) and kept in the incubator for 24 hours at 37
0 
C. The plates with the 
growth were then cooled for two hours at ambient temperature. Gelatinase production 
was indicated by the appearance of a turbid halo around the colonies.  
 ANTIBIOTIC SUSCEPTIBILITY TESTING
72, 73
: 
       Antibiotic sensitivity testing was performed by the Kirby-Bauer’s disc diffusion 
method using Mueller Hinton agar as per CLSI guidelines 2014(M100-S24).  
The quality control strains used were 
              Staphylococcus aureus         -            ATCC 25923 
              Escherichia coli                     -            ATCC 25922 
              Pseudomonas aeruginosa      -            ATCC 27853. 
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 TURBIDITY STANDARD FOR INOCULUM PREPARATION 
For a susceptibility test, density of the inoculum was standardized by a BaSO4 
turbidity standard, which was equal to 0.5 McFarland standards or its optical 
equivalent like latex particle suspension was used.  
Inoculum preparation 
In a sterile test tube isolated colonies (approx. 3-5) belonging to similar 
morphological type was taken and mixed in about 4-5 ml of a suitable broth medium. 
The broth culture was incubated at 35˚C until it attained 0.5 McFarland turbidity 
medium. This suspension corresponds to 150 million organisms/ml. 
 Method of inoculation of test plates 
            The turbidity of the test medium was adjusted and after that it was inoculated 
within 15 minutes into the plates. A sterile cotton swab is immersed into the 
suspension and it is pressed along the sides of the tube. The excess inoculum from the 
swab was removed like this. The swab was then streaked onto a previously dried 
Mueller Hinton agar plate. This procedure was repeated 2-3 times by rotating the plate 
60˚ so that the inoculum got evenly distributed onto the plate. Finally, the rim of the 
plate was swabbed.  Within 15 minutes, the antibiotic discs were impregnated onto the 
plate. The discs were pressed firmly to confirm complete contact with the surface of 
the agar. It was ensured that the discs are placed 24mm from center to center. The 
plate was inverted and kept in the incubator within 15 minutes after the application of 
the drugs. The plate was examined after 16-18 hours of incubation. The zone of 
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inhibition was uniformly circular with a confluent lawn of growth. The diameter of the 
inhibition zone was calculated with the help of sliding calipers or rulers and 
interpreted as per CLSI guidelines 
 TESTS TO DETECT METHICILLIN RESISTANT STAPHYLOCOCCUS 
AUREUS 
CEFOXITIN DISC DIFFUSION TEST
74
 
The test was performed by placing 30µg of cefoxitin disc in the Mueller Hinton 
Agar plate without NaCl supplementation inoculated with test organism. The plate 
was kept in the incubator at a temperature of 37˚C. The zone of inhibition was 
determined after 24 hrs and the zone size was interpreted as 
Susceptible   –    ≥ 20 mm  
Resistant       –   ≤ 19 mm 
METHODS TO DETECT EXTENDED SPECTRUM BETA       
LACTAMASES
51, 53, 54
 
Quality control 
Quality controls were performed using 
Escherichia coli   ATCC 25922            -   Negative control 
Klebsiella pneumoniae ATCC 700603 -   Positive control.  
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Disk diffusion methods 
Disk diffusion test was done for all Enterobacteriaceae isolates against 
cefotaxime (30 µg), ceftriaxone (30 µg), cefpodoxime (10 µg) and ceftazidime (30 µg) 
antibiotic disks for the screening of the isolates for potential ESBL production.  
Overnight incubation was done at 37˚C after which the zone size was read as per 
CLSI recommendations for ESBL screening criteria.  
Phenotypic confirmatory tests or disc potentiation test
75, 76, 77, 78 
This test was done for all enterobacteriaceae isolates against Ceftazidime (30 
µg) antibiotic discs with and without clavunalic acid (10 µg). These discs were placed 
on a Mueller – Hinton agar plate inoculated with bacterial suspension equivalent to 
0.5 McFarland standards. Overnight incubation was done at 37°C after which the 
result was interpreted as follows: 
If the zone diameter of ceftazidime / clavulanic acid was augmented by ≥ 5 mm 
in comparison with ceftazidime alone was taken as ESBL positive. 
 Detection of ESBL Producers using E-test ESBL strip
79, 80
 
                     The ESBL E-strip was based on two gradients. One end of the strip 
contained ceftazidime (0.5-32 µg/ml), and the opposite end was impregnated with 
ceftazidime (0.125-8µg/ml) and clavulanate (4µg/ml).  An overnight culture of the test 
organism on brain – heart infusion agar was suspended in saline to match the 0.5 
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McFarland standard turbidity. Then the suspension was used to inoculate a Mueller 
Hinton agar plate by swabbing the plate using a sterile cotton swab. The E-strip was 
placed on the plate after the plate was dried and it was incubated at 37
0
 C overnight.  
                     For both the ends of the strip, the point of intersection between the 
inhibition eclipse and the edge of the E-strip was considered the minimum inhibitory 
concentration (MIC). A ceftazidime MIC / ceftazidime-clavulanate MIC ratio ≥ 8 
indicates the presence of ESBL enzymes as per the manufacturer’s instruction manual.  
DETECTION OF ESBL GENE BY POLYMERASE CHAIN REACTION 
(PCR)
81
            
Methods for DNA Extraction: 
         DNA extraction was performed with DNA purification kit and by using 
Polymerase chain reaction master mix. 
         Master Mix 2X has 2U of Taq DNA polymerase, 10X Taq reaction buffer, 2mM 
Magnesium chloride, 1µl of 10mM dNTPs mix and Polymerase Chain Reaction 
additives. 
Agarose gel electrophoresis: Requirements 
Agarose, 50X TAE buffer, 6X gel loading buffer, Ethidium bromide. 
 
DNA extraction Procedure: 
The overnight culture of the Escherichia coli and Klebsiella pneumoniae were 
taken in nutrient broth in an amount of 1.5 ml.  It was then centrifuged for 5 minutes 
at 6000 rotations per minute. Then the sediment was taken as the pellet. 
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•  In 200µl of Phosphate Buffer Saline (PBS) pellet was suspended. 
• 180µl of lysozyme Digestion Buffer was mixed to 20 microlitre of lysozyme 
and incubated at 37°C for 15 minutes. 
• 200 microliters of Lysis buffer was mixed with 20µl of Proteinase K [10mg/ml] 
gently, and kept in the water bath at 56°C for ten minutes 
• 300 microlitre of isopropanol was added and mixed well. 
• Whole lysate was transferred into Pure Fast spin column. It was then 
centrifuged at 10000 rpm for one minute 
• Discard flow through and 500µl of Wash Buffer-1 was added and centrifuged 
at 10000 rpm for 1Minute. 
• Discard flow through and 500µl of Wash Buffer-2 was added and centrifuged 
at10000 rpm for 1minute. This step was done twice. 
• Discard flow through centrifuged column for 2 more minutes so that any 
residual ethanol will be removed.   
• 100µl of Elution Buffer was added to elute the DNA, and then centrifuged for 
one minute. 
• Extracted DNA Quality and Quantity was verified by loading in 1% agarose 
gel and 10µL of DNA extracted was used by polymerase chain reaction for 
amplification. 
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Primer 
CTX-M-14 
Forward Primer: 5’- TTATGCGCAGACGAGTGCGGTG - 3’ 
Reverse Primer: 5’- TCACCGCGATAAAGCACCTGCG - 3’ 
PCR Product size: 120bp 
Procedure for PCR: 
[25µl of Master Mix has: 10X Taq buffer, 2mM Magnesium chloride, 0.4mM dNTPs 
mix, and 2U Proofreading Taq DNA polymerase] 
1. Reactions done as follows; 
Components with quantity: 
Master Mix in PCR vial-10µl 
Primer Mix (10pmoles/µl) - 5µl 
Genomic DNA - 5µl 
Total volume - 20µl 
2. All these are mixed gently and spinned down briefly. 
3. Placed into polymerase chain reaction machine and programmed as follows; 
Initial Denaturation: 94ºC for 5 minutes 
Denaturation: 94ºC for 30 seconds               -      35 cycles 
Annealing: 58ºC for 30 seconds                   -        35 cycles 
Extension: 72ºC for 30seconds                    -      35 cycles 
Final extension: 72º C for 5 minutes 
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Loading: 
4. 2% agarose gel was made by mixing 2gm of agarose in 100ml of 1x TAE 
buffer 
5. To 8µl 6X Gel loading dye 15µl of PCR sample was added in PCR vial. 
6. At 50V electrophoresis was run till the dye reaches 3/4th distances and the 
bands were observed in UV Transilluminator. 
 
Method to perform Agarose gel electrophoresis: 
• 2% agarose was made by mixing 2gm agarose in 100ml of 1X TAE buffer; it 
was melted by heating in a microoven. 
• 5µl of Ethidium bromide was added when the agarose gel temperature was 
about 60ºC. 
• Agarose solution which was warm was poured gently into the gel platform. 
• The gel was not disturbed till the agarose got solidified. 
•  Into submarine gel tank 1XTAE buffer was added. 
• Gel platform was kept into tank without disturbance. The tank buffer was 
maintained upto 0.5cm above the gel. 
• Polymerase Chain Reaction samples were loaded and after that they were 
mixed with gel loading dye and along with 10µl HELINI 100bp DNA Ladder. 
• At 50V, electrophoresis was performed till the dye reaches 3/4th distance of the 
agarose gel. 
• The Agarose gel was seen with UV Transilluminator; the bands were seen and 
interpreted.  
66 
 
 
 
 
STATISTICAL ANALYSIS 
         The test outcome was observed, recorded and analysed. The data that were 
analysed was presented in the form of statistical tables, pie charts and histograms if 
necessary in appropriate places.  P values were calculated by Pearson Chi-Square and 
Fishers exact Chi-Square test. The data were documented and studied in detail. The 
documented data was further discussed in detail and compared with other similar 
studies published in reputed scientific journals.        
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RESULTS 
               Antenatal women attending Obstetrics OP at Government Kilpauk Medical 
College and Hospital, Chennai were included in the study for asymptomatic 
bacteriuria detection. The isolates were studied for their virulence factors, Extended 
Spectrum Beta Lactamases (ESBL) and Methicillin Resistant Staphylococcus aureus 
(MRSA).  The study was done between ‘January 2014 to June 2015’. 1000 Antenatal 
women without signs and symptoms of infection of the urinary tract were tested and 
118 bacterial isolates were isolated, identified, their virulence factors were tested and 
analysed for their antibiotic sensitivity pattern.  Resistant isolates were identified and 
studied for Extended Spectrum Beta Lactamases (ESBL) and Methicillin Resistant 
Staphylococcus aureus (MRSA) by various methods. 
            The observations were recorded and analysed.  The results were as follows:     
 
               TABLE-1 Asymptomatic bacteriuria in antenatal women (n=1000) 
 
Out of the 1000 urine samples, 118 (11.8%) were culture positive.  
 
                    
                       ASYMPTOMATIC BACTERIURIA IN ANTENATAL WOMEN 
Total number of Antenatal women 
Antenatal women with Asymptomatic 
bacteriuria 
 
1000 118(11.80%) 
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                   TABLE – 2   AGE WISE DISTRIBUTION (n=118) 
 
Age in years 
 
Culture Positives 
18- 20 28(23.73%) 
21- 30 78(66.10%) 
31- 40 12(10.17%) 
Total 118(100%) 
 
Of the 118 isolates, the asymptomatic bacteriuria was high in the age group of 21-30 
years 78(66.10%). 
TABLE – 3 RELATIONSHIP OF PARITY AND CULTURE POSITIVES 
(n=118) 
 
Gravida 
 
Culture Positives 
Primi gravida 
58(49.2%) 
Second gravida 
41(34.7%) 
Third gravida 
18(15.3%) 
Gravida more than three 
1(0.8%) 
Total 
118(100%) 
  
Out of 118 bacterial isolates, the culture positives were more in the Primigravida 
58(49.2%). 
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TABLE -4    RELATIONSHIP OF DURATION OF PREGNANCY AND 
CULTURE POSITIVES (n=118) 
Trimester Culture positives 
I 46(38.98%) 
II 40(33.89%) 
III 32(27.11%) 
Total 118(11.8%) 
 
Out of the 118 bacterial isolates the culture positives were more in the first  
Trimester 46(38.98%) 
 
TABLE NO.5   SCREENING TESTS FOR ASYMPTOMATIC BACTERIURIA 
IN PREGNANCY (n =1000) 
 
     
PUS CELLS 
DIRECT GRAM 
STAIN SMEAR 
NITRATE 
REDUCTION 
LEUCOCYTE 
ESTERASE 
Culture 
Positivity 
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Positive 
67 51 93 25 89 29 71 47 
Culture 
Negative 
30 852 9 873 11 871 36 846 
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Out of the 118 culture positives, 67 had significant pus cells, 93 had organisms in 
Gram stain, 89 reduced nitrate and 71 were positive for leucocyte esterase by urine 
dipstick. In our study there was statistical significance for all the four screening tests 
with the p value of (p < 0.001)  
TABLE –6 GRAM NEGATIVE BACILLI VS GRAM POSITIVE COCCI 
(n=118) 
ORGANISM PERCENTAGE 
Gram Negative Bacilli 78(66.10%) 
Gram Positive Cooci 40(33.90%) 
 
Out of the 118 isolates, total number of Gram negative bacilli were 78(66.10%) and 
total  number of Gram positive cocci were 40(33.90%)  
TABLE – 7    DISTRIBUTION OF ORGANISMS (n=118) 
ORGANISMS PERCENTAGE 
Escherichia coli 54(45.76%) 
Staphylococcus aureus 21(17.80%) 
Klebsiella pneumoniae 19(16.10%) 
Staphylococcus saprophyticus 
10(8.45%) 
Enterococcus faecalis 9(7.63%) 
Pseudomonas aeruginosa 3(2.54%) 
Proteus mirabilis 2(1.69%) 
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Out of the 118 isolates isolated from 1000 antenatal women, Escherichia coli 
54(45.76%) was the predominant isolate followed by Staphylococcus aureus. Proteus 
mirabilis was the least common organism isolated 2(1.69%). 
TABLE-8 A 
VIRULENCE FACTORS OF ESCHERICHIA COLI (n=54) 
Tests for virulence Virulent Isolates 
Hemolysin 18(33.33%) 
Cell surface hydrophobicity 11(20.37%) 
Serum resistance 11(20.37%) 
Gelatinase test 10(18.51%) 
Mannose Resistant Haemagglutination 9(16.66%) 
Biofilm producers 6(11.11%) 
 
Out of the 54 Escherichia coli isolates, 9(16.66%) were mannose resistant 
haemagglutination positive, 18 (33.33%) were Hemolysin positive, 11(20.37%) were 
Cell Surface Hydrophobicity and Serum Resistance positive. The p-value for 
gelatinase (p=0.042), serum resistance (p=0.011), biofilm (p=0.022) and cell surface 
hydrophobicity (p<0.001) were statistically significant with p value < 0.05.  
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TABLE-8 B 
MULTIPLE VIRULENCE FACTORS OF ESCHERICHIA COLI (n=54) 
Name of the virulence Factors 
No. of Virulent 
Isolates 
Mannose Resistant Haemagglutination + Serum resistance + 
Cell surface hydrophobicity 
1 
Cell surface hydrophobicity+ Serum resistance+ Gelatinase 1 
Serum resistance+ Gelatinase+ Biofilm producers 1 
Hemolysin+  Mannose Resistant Haemagglutination + 
Serum resistance 
1 
Mannose Resistant Haemagglutination+ Gelatinase+ 
Biofilm producers 
1 
Hemolysin+ Cell surface hydrophobicity 4 
Mannose Resistant Haemagglutination+ Gelatinase 1 
Hemolysin+ Biofilm producers 3 
Hemolysin+ Serum resistance 1 
Hemolysin+  Mannose Resistant Haemagglutination 2 
Cell surface hydrophobicity + Gelatinase 2 
Hemolysin+ Gelatinase 3 
Cell surface hydrophobicity+ Serum resistance 2 
Serum resistance + Biofilm producers 1 
Hemolysin Only 4 
Mannose Resistant Haemagglutination Only 3 
Cell surface hydrophobicity Only 0 
Serum resistance Only 4 
Gelatinase test Only 1 
Biofilm producers Only 0 
No Virulence Factors 18 
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Out of the 54 Escherichia coli isolates, 5 isolates had 3 virulence factors positive, 19 
isolates had 2 virulence factors positive and 12 isolates had 1 virulence factor positive. 
18 isolates did not have any of the virulence factor to be positive. 
 
TABLE -9      VIRULENCE FACTORS OF KLEBSIELLA PNEUMONIAE                                   
(n=19) 
Tests for Virulence Virulent Isolates 
Capsule 19(100%) 
Biofilm producers 3(15.78%) 
 
Out of the 19 Klebsiella pneumoniae isolates, capsule was present in 19(100%) and 
3(15.78%) were biofilm producers. 
     TABLE -10 VIRULENCE FACTORS OF PROTEUS MIRABILIS (n=2) 
 
Tests for virulence Virulent Isolates 
Hemolysin 2 
Biofilm producers 1 
Serum resistance 1 
Mannose resistant haemagglutination 1 
 
Out of the 2 Proteus mirabilis isolates, hemolysin was positive in 2. Biofilm producer, 
serum resistance and mannose resistant hemagglutination was positive in 1. 
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 TABLE -11 VIRULENCE FACTORS OF PSEUDOMONAS AERUGINOSA 
(n=3) 
Tests for virulence Virulent Isolates 
Pyocyanin 3 
β-Hemolysin 2 
Biofilm Producers 2 
 
 Out of the 3 Pseudomonas aeruginosa isolates, 3 were pyocyanin producers and 2 
were biofilm producers and β-hemolysin positive.  
TABLE -12 VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS                 
(n=21) 
Tests for Virulence Virulent Isolates 
Slide coagulase test 21(100%) 
Tube Coagulase test 21(100%) 
DNase test 21(100%) 
Urease 21(100%) 
Phosphatase test 20(95.23%) 
Hemolysin 12(57.14%) 
Biofilm producers 8(38.09%) 
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Out of 21 isolates of Staphylococcus aureus, Slide coagulase, Tube coagulase, urease 
and DNase were positive in 21(100%) followed by phosphatase test 20(95.23%), 
Hemolysin 12(57.14%) and Biofilm producers were 8(38.09%). The p-value for 
hemolysin (p=0.007), biofilm (p=0.036), tube coagulase (p=<0.001) and phosphatase 
(p=0.002) were statistically significant. 
 
TABLE -13 VIRULENCE FACTORS OF ENTEROCOCCUS FAECALIS   
(n=9) 
Tests for Virulence Virulent Isolates 
β-Hemolysin 4(44.44%) 
Gelatinase test 2(22.22%) 
Biofilm 2(22.22%) 
 
 Out of the 9 Enterococcus faecalis isolates, 4(44.44%) were β-hemolysin positive, 
2(22.22%) were gelatinase and biofilm producers.  
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TABLE – 14    ANTIBIOTIC SENSITIVITY PATTERN OF 
GRAM NEGATIVE ISOLATES (n=78) 
Name of the 
Drug 
Escherichia 
coli       
(n=54) 
Klebsiella 
pneumoniae 
(n=19) 
Proteus 
mirabilis 
(n=2) 
Pseudomonas 
aeruginosa 
(n=3) 
Amoxycillin  24(44.4)% 7(36.8%) 0 Not tested 
Amoxycillin/ 
Clavulanic acid 
46(85.2%) 9(47.4%) 1(50%) 2(66.7%) 
Cotrimoxazole  39(72.2%) 11(57.9%) 1(50%) 2(66.7%) 
Cephalexin  32(59.3%) 7(36.8%) 0 Not tested 
Cefotaxime  50(92.6%) 17(89.5%) 2(100%) Not tested 
Ceftazidime  50(92.6%) 17(89.5%) 2(100%) 3(100%) 
Gentamicin  35(64.8%) 10(52.6%) 1(50%) 1(33.3%) 
Amikacin  42(77.8%) 15(78.9%) 1(50%) 1(33.3%) 
Norfloxacin  30(55.6%) 10(52.6%) 1(50%) 1(33.3%) 
Ofloxacin  45(83.3%) 13(68.4%) 1(50%) 2(66.7%) 
Nitrofurantoin  48(88.9%) 15(78.9%) 0 3(100%) 
Piperacillin/ 
Tazobactum  
54(100%) 19(100%) 2(100%) 3(100%) 
Imipenem  54(100%) 19(100%) 2(100%) 3(100%) 
 
All the Gram negative bacilli were 100% sensitive to Piperacillin/Tazobactum and 
Imipenem. Nitrofurantoin showed 48(88.9%) and 15(79%) sensitivity to Escherichia 
coli and Klebsiella pneumoniae. Amoxycillin showed 24(44.4%) sensitivity to 
Escherichia coli and 7(36.8%) to Klebsiella pneumoniae. Cefotaxime and ceftazidime 
showed 92.6% and 89.5% sensitivity to Escherichia coli and Klebsiella pneumoniae. 
8
4
 
 
 
C
H
A
R
T
 -
 V
II
I 
 
A
N
T
IB
IO
T
IC
 S
E
N
S
IT
IV
IT
Y
 P
A
T
T
E
R
N
 O
F
 G
R
A
M
 N
E
G
A
T
IV
E
 B
A
C
IL
L
I 
85 
 
TABLE – 15   ANTIBIOTIC SENSITIVITY PATTERN OF 
GRAM POSITIVE ORGANISMS (n=40) 
Name of the Drug 
Staphylococcus 
aureus (n=21) 
Staphylococcus 
saprophyticus 
(n=10) 
Enterococcus 
faecalis (n=9) 
Amoxycillin 8(38.09%) 5(50%) 3(33.33%) 
Amoxycillin/clavulan
ic acid 
19(90.47%) 10(100%) 6(66.66%) 
Cotrimoxazole 10(47.62%) 10(100%) 5(55.55%) 
Cephalexin 9(42.85%) 7(70%) Not tested 
Cefotaxime 15(71.42%) 8(80%) Not tested 
Gentamicin 10(47.62%) 6(60%) 5(55.55%) 
Amikacin 15(71.42%) 8(80%) 6(66.66%) 
Norfloxacin 9(42.85%) 6(60%) 6(66.66%) 
Ofloxacin 17(80.95%) 9(90%) 8(88.88%) 
Nitrofurantoin 16(76.19%) 8(80%) 7(77.77%) 
Vancomycin 21(100%) 10(100%) 9(100%) 
 
All the Gram positive cocci were 100% sensitive to Vancomycin. Staphylococcus 
aureus and Staphylococcus saprophyticus showed 79.19% and 80% sensitivity to 
Nitrofurantoin. Staphylococcus aureus isolates were tested for Methicillin resistant 
Staphylococcus aureus using Cefoxitin disk. None of the Staphylococcus aureus 
isolates were Methicillin resistant Staphylococcus aureus. 
8
6
 
 
C
H
A
R
T
 -
 I
X
 
 
A
N
T
IB
IO
T
IC
 S
E
N
S
IT
IV
IT
Y
 P
A
T
T
E
R
N
 O
F
 G
R
A
M
 P
O
S
IT
IV
E
 I
S
O
L
A
T
E
S
 
87 
 
TABLE – 16    SCREENING TEST FOR ESBL DETECTION AMONG THE 
ENTEROBACTERIACEAE (n=75) 
Organism Total Number of Organisms 
Resistant to cefotaxime and 
ceftazidime 
Escherichia coli 54 4(7.4%) 
Klebsiella pneumoniae 19 2(10.5%) 
Proteus mirabilis 2 0 
 
Out of 75 Enterobacteriaceae isolates, 4(7.4%) Escherichia coli and 2(10.5%) 
Klebsiella pneumoniae were positive by the screening test. None of Proteus mirabilis 
isolates were positive in the screening test.   
TABLE-17     ESBL PRODUCERS BY PHENOTYPIC CONFIRMATORY 
TEST (n=75) 
Organism Total Number of Organisms 
Phenotypic confirmatory 
test 
Escherichia coli 54 4(7.4%) 
Klebsiella pneumoniae 19 2(10.5%) 
Proteus mirabilis 2 0 
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By the phenotypic confirmatory test, 4(7.4%) Escherichia coli and 2(10.5%) 
Klebsiellae pneumoniae were identified as ESBL producers. None of the Proteus 
mirabilis isolates were positive for ESBL. 
TABLE- 18    MINIMUM INHIBITORY CONCENTRATION OF ESBL 
POSITIVE ISOLATES USING E-STRIP CONTAINING CEFTAZIDIME AND 
CEFTAZIDIME/CLAVULANIC ACID (n=6) 
              
Serial 
number 
Name of the  
Organism 
C
ef
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+
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1. Escherichia coli >32 0.25 128 Positive 
2. Escherichia coli 6 0.125 48 Positive 
3. Escherichia coli >32 0.25 128 Positive 
4. Escherichia coli 3 0.5 6 Negative 
5. K.pneumoniae 6 0.125 48 Positive 
6. K.pneumoniae 3 0.75 4 Negative 
 
Of the 4 ESBL positive Escherichia coli, 3(75%) and of the 2 ESBL positive 
Klebsiella pneumoniae 1(50%) showed ≥ 8 times reduction in Minimum Inhibitory 
Concentration. 
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Table - 19  GENE IDENTIFICATION IN ESBL POSITIVE ISOLATES FOR           
TEM, SHV and CTX-M (n=6) 
Organism 
Total 
Tested 
TEM 
Positive 
SHV 
Positive 
CTX –M 
Positive 
Escherichia coli 4 0 0 2 
Klebsiella pneumoniae 2 0 0 1 
 
Of the 6 ESBL producers, 3 were positive for CTX-M gene. 2 were Escherichia coli 
and 1 was Klebsiella pneumoniae.  None of the isolates were positive for the TEM and 
SHV gene. 
     Table - 20  GENE IDENTIFICATION IN MANNOSE RESISTANT 
HAEMAGGLUTINATION  POSITIVE  ISOLATES FOR Pap A GENE BY 
PCR 
Organism 
Mannose Resistant 
Haemagglutination positive 
Escherichia coli isolates 
(P fimbriae) 
Pap A GENE 
% 
Escherichia coli 9 9(100%) 
 
Of the 54 Escherichia coli isolates, 9 were positive to mannose resistant 
hemagglutination test by phenotypic method and they were positive by genotypic 
method. 
90 
 
91 
 
 
92 
 
93 
 
94 
 
95 
 
96 
 
97 
 
98 
 
99 
 
100 
 
101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                      DISCUSSION 
102 
 
DISCUSSION 
                This study aims at determining the common bacterial isolates causing 
asymptomatic bacteriuria in pregnancy, the virulence factors of various isolates, their 
antimicrobial susceptibility pattern and the extended spectrum beta lactamase 
producers. This study was conducted from January 2014 to June 2015 among 1000 
antenatal women from 18 to 40 years of age without any symptoms of urinary tract 
infection.  The observations were recorded, analysed and discussed as follows. 
                As per table – 1, Number of culture positive urine samples were 
118(11.8%). This was coinciding with the studies done by Sanyogita Jain et al
9
 11%, 
Rajashekar et al
12
 11%, Anandhi Kasinathan et al
28
 12.6%, whereas Sudha Birader 
Kerure et al
11
 had 9%, SV Lavanya et al
4
 8.4%, Kheya mukherjee et al
37
 8.4%, R 
Sujatha et al
6
 7.3% and Gayathree L et al
61
 6.2%, 
           As per table – 2, the age groups included were from 18-40 years. Pregnant 
women in the age group of 21-30 years were more culture positive 78(66.10%). This 
was in accordance to the study done by R Sujatha et al
6
 16(72.72%) and Chandel lata 
R et al
10
 91.2% whereas in a study done by S V Lavanya et al
4
 the culture positivity 
was significant in the < 20 years age group 71.42%, while in a study done by 
Jeyaseelan et al
7
 it was significant in the > 30 years age group 53.5%. The reason may 
be due to that, women of this age group are mostly multiparous, and multiparity is a 
risk factor for getting asymptomatic bacteriuria in pregnancy.  
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              As per table – 3, Urine samples were collected upto gravida 4. The culture 
positives in asymptomatic bacteriuria were higher in the primigravida 58(49.2%).  
These findings were in accordance with the observations done by Chandel Lata R et 
al
10
 52.9%, Kheya Mukherjee et al
37
 11(52.38%), Sudha Birader Kerure et al
11
 56%, 
Rajashekar et al
12
 59%, S V Lavanya et al
4
 28(66.6%). This was in contrast to the 
study done by R Sujatha et al
6
 for whom the culture positives were significant in 
multigravida 51.1%. The higher incidence in primigravida may be because 
physiological and anatomical changes are more marked in primigravida. 
   As per table – 4, all the three trimesters were included in the study. The culture 
positives in asymptomatic bacteriuria were significant in the first trimester 38.98% in 
this study. This was similar to the study done by by R Sujatha et al
6
 45.45%. This was 
in contrast to the study done by Kheya Mukherjee et al
37
 for whom the culture 
positives were more in the second trimester 42.86%, and in a study done by Gayathree 
et al
61
 it was in the third trimester 61.77%. Hormonal changes occurring prior to the 
anatomical changes may be the reason behind.   
            As per table – 5, Pus cells were present in 67(56.7%) by wet mount method. 
This was in accordance with the study done by Kheya mukherjee et al
37
and J 
Jayalakshmi et al
17
, whereas in a study done by Sushama S et al
40
 it was 72.41%. 
           Direct Gram stain smear positive for organisms were 93(78.81%). This was 
similar to the studies done by J Jayalakshmi et al
17
 and Kheya mukherjee et al
37
 
whereas in a study done by Gayathree et al
61
 it is 90.32%. 
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                  Among the screening tests, leukocyte esterase test was positive in 
71(60.16%) by dipstick in this study. This was similar to the study done by Kheya 
mukherjee et al
37
, J Jayalakhmi et al
17
 and Gayathree et al
61
. This was in contrast to 
the study done by A Titoria et al
60 
(27.5%). 
                  Nitrite test was positive in 89(75.4%) by dipstick method. This was similar 
to the studies done by J Jayalakshmi et al
17
, Kheya Mukherjee et al
37
 and Gayathree et 
al
61
. 
                As per table 6, Gram negative bacilli 78(66.10%) were the predominant 
organisms isolated than the Gram positive cocci 40(33.90%). This finding was similar 
with the findings reported by Sanyogita Jain et al
9
, Kheya mukherjee et al
37
, R Sujatha 
et al
6
, T. Jeyaseelan Senthinath et al
7
 and Chandel Lata R et al
10
.   
                As per table 7, The predominant organism isolated was Escherichia coli 
54(45.76%), which was in accordance with the study done by Gayathree L et al
61
, SV 
Lavanya et al
4
, Ananthi Kasinathan et al
28
, Sudha Biradar Kerure et al
11
, Chandel Lata 
et al
10
, R.Sujata et al
6
, Sanyogita Jain et al
9
, A.Titoria et al
60
, Kheya Mukherjee et al
37
 
and Imade et al
85
. In a study done by Ajayi AB et al
87 
in Nigeria, Staphylococcus 
aureus was the most common organism isolated which was 70%, a contrast 
observation.   
               Next to Escherichia coli, the organism most commonly isolated was 
Staphylococcus aureus 21(17.80%). Chandel Lata et al
10
, Imade et al
85
, Sudha Biradar  
 
 
105 
 
Kerure et al
11
 and Rajashekar et al
12
 also reported Staphylococcus aureus next to 
Escherichia coli which was similar to this study.  
              Next to Staphylococcus aureus, the organisms isolated were Klebsiella 
pneumoniae 19(16.10%), Staphylococcus saprophyticus 10(8.45%), Enterococcus 
faecalis 9(7.63%), Pseudomonas aeruginosa 3(2.54%) and Proteus mirabilis 2(1.69%).     
              As per table – 8A, among the virulence factors of Escherichia coli, hemolysin 
was the predominant virulence factor 18(33.33%).  This was similar to the study done 
by R Raksha et al
2
. Colonisation with haemolytic strains of Escherichia coli are more 
prone to develop into urinary tract infections.  
                  Shruthi N et al
1
 and Rebecca Naveen et al
34
, showed mannose resistant 
haemagglutination as the predominant virulence factor and in studies done by             
S Sharma et al
63
 and Rohini P et al
84
, serum resistance was the predominant virulence 
factor.  The other virulence tests that were positive were cell surface hydrophobicity 
and serum resistance 11(20.37%), gelatinase 10(18.51%), mannose resistant 
hemagglutination 9(16.66%) and biofilm producers were 6(11.11%). Saroj Golia et 
al
65
 had no biofilm positive isolates among the asymptomatic bacteriuria patients and 
this is a contrast study. 
                As per table- 8B, Out of the 54 Escherichia coli isolates, 5 isolates had 3 
virulence factors positive, 19 isolates had 2 virulence factors positive and 12 isolates 
had 1 virulence factor positive. 18 isolates did not have any of the virulence factors to 
be positive. Similarly, Shruthi N et al
1
had three virulence factors positive in her study.  
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In a study done by S Sharma et al
63
, expression of multiple virulence factors by extra 
intestinal Escherichia coli was revealed.   
            As per table - 9, among the virulence factors of Klebsiella pneumoniae, 
capsule was present in 19(100%) and the biofilm producers were 3(15.78%). Biofilm 
was positive in Klebsiella pneumoniae in a study done by Hassan et al
86
. 
              As per Table – 10, among the virulence factors of Proteus mirabilis, 
hemolysin was positive in 2. Biofilm producer, mannose resistant hemagglutination 
and serum resistance was positive in 1. This was similar to the studies done by M 
Mishra et al
68
 and R Wasfi et al
33
. 
          As per table – 11, among the virulence factors of Pseudomonas aeruginosa, 
biofilm producers and β-hemolysin was positive in 2 and pyocyanin was positive in 3. 
Pyocyanin production was considered as a virulence factor in the studies done by P 
Gupta et al
70
 and Lars E.P. Dietrich et al
69
. 
          As per table - 12, among the virulence factors of Staphylococcus aureus, slide 
coagulase, tube coagulase, urease and DNase were positive in 21(100%), phosphatase 
was positive in 20(95.23%), biofilm producers were 8(40%), hemolysin was positive 
in 12(60%). 
           As per table – 13, among the virulence factors of Enterococcus faecalis 
gelatinase was positive in 2(22.22%), hemolysin was positive in 4(44.44%) and 
biofilm producers were 2(22.22%).  This was similar to the study done by Praharaj Ira 
et al
71
. Biofilm shows increased resistance to broad spectrum antibiotics. So biofilm 
adds to the virulence profile of microorganisms. 
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As per table – 14, All the Gram negative bacilli were 100% sensitive to 
Piperacillin/Tazobactum and Imipenem. This was similar to the study done by Girish 
Babu et al
82
. Cefotaxime and ceftazidime showed 50(92.6%) sensitivity to Escherichia 
coli.  Nitrofurantoin showed 48(88.9%) sensitivity to Escherichia coli and 15(79%) 
sensitivity to Klebsiella pneumoniae. Amoxycillin showed 24(44.4%) sensitivity to 
Escherichia coli and 7(36.8%) sensitivity to Klebsiella pneumoniae. 
                 In a study done by Girish Babu et al
82
, Nitrofurantoin showed increased 
sensitivity compared to Cefotaxime and Ceftazidime whereas in this study cefotaxime 
and ceftazidime were more sensitive compared to nitrofurantoin for the Escherichia 
coli and Klebsiella pneumoniae isolates.  
              As per table – 15, All the Gram positive cocci were 100% sensitive to 
Vancomycin. Staphylococcus aureus and Staphylococcus saprophyticus showed 
79.19% and 80% sensitivity to Nitrofurantoin.  Amoxycillin and 
amoxycillin/clavulanic acid showed 8(38.09%) and 19(90.47) sensitivity to 
Staphylococcus aureus.   Amoxycillin showed 5(50%) sensitivity to Staphylococcus 
saprophyticus and 3(33.30%) to Enterococcus faecalis.  This was similar to a study 
done by Kheya Mukherjee et al
37
.  
              As per table – 16, ESBLs were screened by observing resistance to third 
generation cephalosporins, cefotaxime and ceftazidime. Out of 54 Escherichia coli 
isolates, 4 were positive and out of 19 Klebsiella pneumoniae isolates, 2 were positive.  
None of the Proteus mirabilis isolates were positive for ESBL. 
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                  As per table – 17,  Escherichia coli and Klebsiella pneumoniae isolates 
which were resistant to 3
rd
 generation cephalosporins were further confirmed by the 
phenotypic confirmatory test. Among the 6 ESBL producers, 4 were Escherichia coli 
and two were Klebsiella pneumoniae isolates. In a study done by R Sujatha et al
6
, out 
of the 17 Escherichia coli isolates, 1 was an ESBL producer.   
                   As per table – 18, Minimum inhibitory concentration (MIC) was done by 
the E - strip using ceftazidime and ceftazidime/clavulanic acid. 3(75%) were positive 
for Escherichia coli and 1(50%) was positive for Klebsiella pneumoniae. A 
ceftazidime: ceftazidime/clavulanic acid MIC ratio of ≥ 8 was considered as a positive 
result for ESBL production. 
                   As per table – 19, By polymerase chain reaction, 2 out of 4 Escherichia 
coli and 1 out of 2 Klebsiella pneumoniae were confirmed for CTX- M gene and none 
were positive for the the TEM and SHV genes.  
                   As per table – 20, by polymerase chain reaction, 9(100%) which were 
positive for mannose resistant haemagglutination by phenotypic method were positive 
for the pap A gene. The pap A gene was positive in the following studies done by AV 
Shetty et al
16
, Francisco Toval et al
66
, J Agarwal et al
83
, Jean – Philippe Lavigne et 
al
67
, and Akira Takahashi et al
36
. 
 As asymptomatic bacteriuria is related to the complications in pregnancy, it is 
therefore imperative that pregnant women be tested for bacteriuria, periodically in 
every trimester of the gestational period. Urine culture tests should be done routinely  
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for all the pregnant women to find out asymptomatic bacteriuria, and every positive 
case should be managed with appropriate antibiotics, to prevent any complication 
related to pregnancy. In view of the changing patterns of bacterial resistance to 
common drugs, the administration of antibiotics must be done cautiously to prevent 
the emergence of bacterial resistance in the hospital and the community.                                                          
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SUMMARY 
Mid stream clean catch urine specimens were collected from one thousand 
antenatal women without any symptoms of urinary tract infection who attended 
Obstetrics and Gynaecology out patient department at Government Kilpauk Medical 
College Hospital, Chennai from January 2014 to June 2015. Urine samples were 
collected from pregnant women of different age groups, gravida and trimesters. 
The culture positives with asymptomatic bacteriuria in pregnancy were 11.8%.  
The culture positives were more in the 21-30 years age group, primigravida and in the 
first trimester. Gram negative bacilli were 78(66.10%) the predominant bacteria 
isolated in women with asymptomatic bacteriuria in antenatal women.   
Escherichia coli was the major isolate constituting 54(45.76%) followed by 
Staphylococcus aureus 21(17.8%).   
Among the virulence factors of Escherichia coli, hemolysin was the major 
virulence factor constituting 18(33.33%) followed by cell surface hydrophobicity, 
serum resistance, gelatinase, mannose resistant hemagglutination and biofilm 
production. 
Among the virulence factors of Staphylococcus aureus, slide, tube coagulase, 
urease and DNase were positive in 21(100%) followed by Phosphatase, Hemolysin 
and biofilm production. 
Among the virulence factors of Klebsiella pneumoniae, capsule was present in 
19(100%) and 3(15.78%) were biofilm producers. 
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Among the virulence factors of Enterococcus faecalis, hemolysin was positive 
in 4(44.44%), gelatinase and biofilm producers were 2(22.22%). 
Among the virulence factors of Pseudomonas aeruginosa, pyocyanin was 
positive in 3, hemolysin and biofilm producers were 2. 
          Among the virulence factors of Proteus mirabilis, hemolysin was positive in 2, 
biofilm, serum resistance and mannose resistant hemagglutination were positive in 1. 
          In the present study, antibiotic sensitivity of all Enterobacteriaceae showed 
100% sensitivity to imipenem and piperacillin/tazobactam. Pseudomonas aeruginosa 
showed 3(100%) sensitivity to piperacillin /Tazobactam and imipenem. Escherichia 
coli 48(88.9%), Klebsiella pneumoniae 15(79%), Pseudomonas aeruginosa 3(100%) 
and Proteus mirabilis 0% showed sensitivity to nitrofurantoin. Amoxycilllin showed 
less than 45% sensitivity to all the Gram negative isolates. Cefotaxime and 
ceftazidime showed 92.6% and 89.5% sensitivity to Escherichia coli and Klebsiella 
pneumoniae 
            Antibiotic sensitivity testing of Staphylococcus aureus showed 100% 
sensitivity to vancomycin. Among 21 Staphylococcus aureus, 17(80.95%) were 
sensitive to amoxicillin-clavulanic acid, 16(76.19%) to nitrofurantoin and 9(42.85%) 
to cephalexin. Enterococcus faecalis 9(100%) and Staphylococcus saprophyticus 
10(100%) were sensitive to vancomycin.  None of the Staphylococcus aureus isolates 
were Methicillin Resistant Staphylococcus aureus. 
           ESBLs were screened by detecting resistance to third generation 
cephalosporins, cefotaxime and ceftazidime. Out of 75 Gram negative bacilli 6(8%) 
113 
 
were ESBL producers. Out of 54 Escherichia coli, 4(7.4%) and out of 19 Klebsiella 
pneumoniae, 2(10.5%) were ESBL producers. Proteus mirabilis showed 100% 
sensitivity to both the cephalosporins. 
                4 Escherichia coli and 2 Klebsiella pneumoniae were positive by the 
phenotypic confirmatory test. Minimum inhibitory concentration (MIC) was done 
with E-strip containing ceftazidime and ceftazidime with clavulanic acid for the ESBL 
producers.  Of the 4 ESBL positive Escherichia coli, 3(75%) were positive and of the 
2 ESBL positive Klebsiella pneumoniae 1(50%) was positive showing a ceftazidime 
and ceftazidime/clavulanate MIC ratio of ≥ 8. 
               6 ESBL producing Enterobacteriaceae which were phenotypically confirmed 
as ESBL positives were subjected to genotypic test by Polymerase Chain Reaction 
(PCR). Three genes such as TEM, SHV and CTX-M associated with ESBL 
production were studied using the relevant primers for the corresponding genes. CTX-
M was detected in 3(50%). 9 Mannose resistant haemagglutination positive 
Escherichia coli isolates were positive for the pap A gene.  
    In the present study, all the 21 Staphylococcus aureus isolates were 
Methicillin sensitive Staphylococcus aureus and none were found to be Methicillin 
resistant Staphylococcus aureus.   
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                                                       CONCLUSION 
• The present study showed that Gram negative bacilli 78(66.10%) were the 
predominant bacteria isolated in asymptomatic bacteriuria in antenatal women. 
• Among the Gram negative bacilli, Escherichia coli 54(45.76%) was found to be 
the most common bacterial pathogen isolated and Staphylococcus aureus was 
the most common Gram positive organism isolated followed by Klebsiella 
pneumoniae. 
• Among the Escherichia coli isolates, hemolysin was the major virulence factor 
constituting 18(33.33%), followed by cell surface hydrophobicity, serum 
resistance, gelatinase, mannose resistant hemagglutination and biofilm 
production. 
•  Among the virulence factors of Staphylococcus aureus, slide coagulase, tube 
coagulase, urease and DNase were positive in 21(100%), followed by 
phosphatase, hemolysin and biofilm. 
• Among the Enterobacteriaceae isolates, 6(8%) were found to be ESBL 
producers and all of them showed 100% sensitivity to imipenem. 
• Among Gram positive organisms, Staphylococcus aureus was the predominant 
isolate. 
• Among the Staphylococcus aureus isolates, none were found to be MRSA. 
• The present study showed high occurrence of asymptomatic bacteriuria in 
pregnant women which if not treated, might lead to various maternal and 
neonatal complications. Urine culture with clean catch mid stream urine is the 
most sensitive test for its detection preferably in the first trimester. All the 
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sequelae of asymptomatic bacteriuria during pregnancy could be reduced by 
antimicrobial treatment early in pregnancy. Hence, screening and management 
of asymptomatic bacteriuria need to be incorporated as a routine antenatal care 
for an integrated approach to safe motherhood and newborn health.     
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PROFORMA 
Name  :        IP no: 
Age  :        Ward: 
Sex  : 
Occupation : 
Address :  
Gravida : 
Para  :  
LMP  : 
EDD  : 
 Underlying illness : 
• Diabetes mellitus. 
• Hypertension 
• Others 
 
 Procedures: 
• Catheterization 
 
 Prior antibiotic therapy : 
Laboratory evaluation: 
 Sample collection        Date 
Microbiological investigation: 
 Macroscopic examination: 
 Microscopic examination: 
 Gram Stain 
 Wet film 
 Culture: 
Bacterial culture 
 Antimicrobial sensitivity pattern: 
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Ra xg;Gjy; gbtk; 
Ma;T nra;ag;gLk; jiyg;G : “ISOLATION AND CHARACTERISATION OF 
BACTERIAL PATHOGENS CAUSING ASYMPTOMATIC BACTERIURIA IN ANTENATAL 
WOMEN ATTENDING TERTIARY CARE HOSPITAL” 
Ma;T nra;ag;gLk; ,lk;: fPo;g;ghf;fk; muR kUj;Jtf;fy;Y}hp kw;Wk; 
kUj;Jtkid> nrd;id -10 
gq;F ngWgthpd; ngah;: 
gq;F ngWgthpd; taJ:   gq;F ngWgthpd; vz;: 
  
 NkNy Fwpg;gpl;Ls;s kUj;Jt Ma;tpd; tptuq;fs; vdf;F 
tpsf;fg;gl;Ls;sJ. ehd; ,t;tha;tpy; jd;dpr;irahf gq;Nfw;fpd;Nwd;. ve;j 
fhuzj;jpdhNyh> ve;j rl;l rpf;fYf;Fk; cl;glhky; ehd; ,t;tha;tpy; 
,Ue;J tpyfpf; nfhs;syhk; vd;W mwpe;J nfhz;Nld;. 
 ,e;j Ma;T rk;ge;jkhfNth> ,ij rhh;e;J NkYk; Nkw;nfhs;Sk; NghJk; 
,e;j Ma;tpy; gq;FngWk; kUj;Jth; vd;Dila kUj;Jth; vd;Dila 
kUj;Jt mwpf;iffis ghh;g;gjw;F vd; mDkjp Njit ,y;iy vd 
mwpe;J nfhs;fpNwd;. ,e;j Ma;tpd; %yk; fpilf;Fk; jftiyNah> 
KbitNah gad;gLj;jpf; nfhs;s kWf;fkhl;Nld;. 
 ,e;j Ma;tpy; gq;F nfhs;s xg;Gf; nfhs;fpNwd;. ,e;j Ma;it 
Nkw;nfhs;Sk; kUj;Jt mzpf;F cz;ikAld; ,Ug;Ngd; vd;W 
cWjpaspf;fpNwd;. 
gq;Nfw;gthpd; ifnahg;gk;    rhl;rpahshpd; ifNahg;gk; 
,lk;:     ,lk;: 
Njjp:     Njjp: 
gq;Nfw;gthpd; ngah; kw;Wk; tpyhrk;: 
Ma;thshpd; ifnahg;gk;: 
,lk;:   Njjp: 
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APPENDIX 
 
GRAM STAIN 
Primary stain - Crystal violet 10g 
Absolute alcohol - 100ml, Distilled water 1 litre 
Grams iodine - iodine 10g 
Potassium iodide 20g, Distilled water -1 litre 
Acetone 
Counter stain-dilute carbolfuchsin 
1. Flood the crystal violet for one minute 
2. Rinse gently with distilled water 
3. Flood the slide with Gram’s iodine for one minute 
4. Rinse gently with distilled water 
5. Decolourise with acetone for only 2-3 seconds. 
6. Rinse gently with distilled water to remove excess of decolouriser 
7. Flood the slide with dilute carbolfuchsin for one minute 
8. Rinse the slide with distilled water, air dry and examine under oil immersion 
objective 
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PEPTONE WATER 
Peptone   10g 
Sodium chloride  5g 
Distilled water   1 litre 
 
Dissolve the ingredients in warm water, adjust the pH to 7.4 - 7.5 and filter. 
Distribute as required and autoclave at 121 degree celsius for 15 minutes. 
 
Mac Conkey agar:- 
This is a useful medium for the cultivation of Enterobacteriaceae. It contains a 
bile salt to inhibit non-intestinal bacteria and lactose with neutral red to distinguish the 
lactose- fermenting coli forms from the lactose-non-fermenting salmonella and 
shigella groups. The concentration of sodium taurocholate may be reduced to suit less 
tolerant organisms. The omission of sodium chloride from the medium prevents the 
spreading of Proteus colonies. 
Peptone       20 g 
Sodium taurocholate, commercial    5 g 
Water        1 litre 
Agar        20 g 
Neutral red solution, 2% in 50% ethanol    3.5 ml  
Lactose, 10% aqueous solution    100 ml  
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Dissolve the peptone and taurocholate (bile salt) in the water by heating. Add 
the agar and dissolve it in the steamer or autoclave. If necessary, clear by filtration. 
Adjust the pH to 7.5. Add the lactose and the neutral red, which should be well shaken 
before use, and mix. Heat in the autoclave with 'free steam' ( 100
o
 C) for 1hour, then 
at 115
o
 C for 15 min. Pour plates. 
 
NUTRIENT AGAR:-     grams/litre 
Peptic digest of animal tissue    5.00 
Beef extract       1.50 
Yeast extract       5.00 
Agar        15.00 
 
Dissolve the contents in water and mix by heating Autoclave at 121
o
 C for 15 
minutes. Adjust pH to 7.4 + 0.2. Pour 20-25 ml into 9 cm diameter petridishes to give 
4 mm thickness. 
 
BLOOD AGAR: 
Sterile sheep blood      50 ml 
Peptone       10 g 
Beef extract       3g 
Sodium chloride      5 g 
Distilled water      1000 ml 
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Autoclave the nutrient agar base at 121
o
 C for 15 minutes and then add blood 
when the nutrient agar is cooled to 50
0
C with sterile precautions and distribute in Petri 
dishes.  
 
MUELLER HINTON AGAR:- 
Beef infusion     300 ml 
Casein Hydrolysate    17 gm 
Starch      1.5 gm 
Agar      10 gm 
Distilled water    1000 ml  
 
Emulsify the starch in a small amount of cold water, pour into the beef infusion 
and add the casein-hydrolysate and the agar. Make up the volume to 1000 ml (1 litre) 
with distilled water. Dissolve the constituents by heating gently at 100
o
 C with 
agitation. 
           Adjust the pH to 7.4. Dispense in screw-capped bottles and sterilize by 
autoclaving at 121 
o
 C for 20 minutes. 20 to 25 ml of it is poured into petridishes of 9 
cm diameter to give a thickness of 4mm. 
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McFarland's Turbidity Standard for inoculum preparation 
 
A Barium sulphate 0.5 McFarland standards was prepared as follows 
1. A 0.5 ml of 0.048mol/L of Barium chloride was added to 99.5 ml of 0.18 
mol/L of H2SO4 with constant stirring to maintain a suspension. 
2. Correct density of the turbidity standard was verified by using a 
spectrophotometer. The absorbance of 625nm should be 0.08 to 0.10 for the 
0.5 McFarland standards. 
3. The Barium sulphate suspension was transferred in 4-6 ml to a screw capped 
tube of the same size as those used in growing or diluting the bacterial 
inoculum. 
4. These tubes were tightly sealed and stored in the dark at room temperature. 
5. The Barium sulphate turbidity standard was vigorously agitated before each use 
and inspected for a uniform turbid appearance. 
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Differentiating Characters of Isolates Commonly Observed In Samples of 
Asymptomatic Bacteriuria in Antenatal Women 
Organism TSI 
C
it
ra
te
 
In
d
o
le
 
O
x
id
a
se
 
C
a
ta
la
se
 
U
re
a
se
 
G
lu
c
o
se
 
L
a
ct
o
se
 
S
u
cr
o
se
 
M
a
lt
o
se
 
M
a
n
n
o
se
 
M
o
ti
li
ty
 
Escherichia coli A/A with gas Not 
utilised 
+ - + - 
 
+ + - + + + 
Klebsiella 
pneumoniae 
A/A with gas utilised - - + + + + + + + - 
Proteus species K/A with H2S variable ± - + + + - - - - + 
Pseudomonas 
aeruginosa 
K/No change utilised - + + - + - - + - + 
 
Note: A/A = Acid slant / Acid butt, + = Positive, - = Negative, v - Variable 
 
Differentiating Characters Of Isolates Commonly Observed In Samples of 
Asymptomatic Bacteriuria in Antenatal Women 
 
Gram 
strain 
Catalase Oxidase Hemolysis Coagulase Mannitol 
Bile 
esculin 
agar 
Novobiocin Isolate 
Cocci  in  
cluster 
Positive negative ± Positive Positive Negative Sensitive 
Staphylococcus  
aureus 
Cocci  in  
cluster 
Positive negative ± Negative Negative Negative Resistant 
Staphylococcus 
saprophyticus 
Cocci  in 
pairs 
Positive negative ± Negative Negative Positive - 
Enterococcus 
species 
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ZONE SIZE INTERPRETATIVE CHART IN ACCORDING TO NCCLS 
Kirby-Bauer Chart 
Sl. 
No. 
Drug 
Disk Content 
µg 
Resistant mm 
or less 
Intermediate 
mm 
Sensitive mm 
or more 
1 Amoxycillin 10  14 mm 15-16 mm 17 mm 
2 Cotrimoxazole 1.25/23.75 10 11-15 16 
3 Cephalexin 30 14 15-17 18 
4 Ofloxacin 5 12 13-15 16 
5 Ciprofloxacin 5 15 16-20 21 
6 Gentamicin  10 12 13-14 15 
7 Cefotaxime 30 14 15-22 23 
8 Ceftazidime 30 14 15-17 18 
9 Linezolid 30 - - 21 
10 Amikacin 30 14 15-16 17 
11 Imipenem 10 13 15-16 16 
12 
Piperacillin/tazobact
um 
100/10 17 18-20 21 
13 Vancomycin 30 - - 15 
14 Nitrofurantoin 300 14 15-16 17 
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ABBREVIATION 
 
ATCC   - American Type Culture Collection. 
CLSI   - Central Laboratory Standards Institute 
CLED   - Cysteine Lactose Electrolyte Deficient  
CFU   - Colony Forming Units. 
ESBL   - Extended Spectrum Beta Lactamase 
E- Test  - Epsilometer Test 
IUGR                     -          Intra Uterine Growth Retardation 
MHA   - Mueller Hinton Agar 
MIC   - Minimum Inhibition Concentration 
PCR   - Polymerase Chain Reaction 
PBP   - Pencillin Binding Protein 
SHV   - Sulphy Hydryl Variable 
TTC                       -           Triphenyl Tetrazolium Chloride Test 
TEM    - Temoniera 
UTI                        -          Urinary Tract infection 
UPEC                    -           UroPathogenic Escherichia coli 
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KEY TO MASTER CHART 
OP No                              -              Outpatient number 
G                                         -               Gravida 
P                                          -                Para 
L                                         -               Live birth 
GA                                      -                Gross appearance 
NG                                      -                No growth 
GNB                                   -                Gram Negative Bacilli 
GPC                                   -                Gram Positive Cocci 
AMX                                 -                 Amoxycillin 
AMC                                    -                  Amoxycillin + Clavulanic    acid 
E                                       -                  Erythromycin 
CN                                   -                  Cephalexin 
CTX                              -                     Cefotaxime 
CAZ                                   -                     Ceftazidime 
AK                                       -                     Amikacin 
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GEN                               -                     Gentamicin 
OF                                    -                     Ofloxacin 
NX                                    -                     Norfloxacin 
NIT    -  Nitrofurantoin 
COT                                    -                  Cotrimoxazole 
PIT                                      -                   Piperacillin+Tazobactum 
IMP                                   -                    Imipenem 
VAN                                 -                 Vancomycin 
CX                                 -                  Cefoxitin 
S                                        -                    Sensitive 
R                                       -                   Resistant 
ESBL                            -                  Extended Spectrum Beta Lactamases 
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1 5265 26 G2P1L1 II clear + - - - NG
2 1027 28 Primi III clear - - + - NG
3 5252 23 G2P1L1 III clear - - - + NG
4 1009 34 Primi II clear - - - - NG
5 1024 24 Primi III turbid + - + + Escherichia coli + + + R S R R R S S R S R S S S ESBL
6 1018 24 Primi I clear - - - - NG
7 852 21 Primi III clear - - - + NG
8 90 25 Primi II clear - - - + NG
9 1097 24 Primi II clear + + + - Staphylococcus aureus + + + + + + R R R S S S S R S S S S
10 864 22 Primi II clear - - - - NG
11 992 27 G3P2L1 III clear - - - + NG
12 1144 21 Primi III clear + - - - NG
13 1021 19 Primi III turbid - - - - NG
14 1114 34 G2P1L1 II clear - - - - NG
15 1145 30 G2P1L1 III turbid + + + + Klebsiella pneumoniae + S R S S S S S R S S S S S
16 4842 25 G2P1L1 III clear - - - + NG
17 1112 28 G3P1L1A1 III clear - - - - NG
18 1134 29 G3P2L2 III clear - - - + NG
19 1217 30 G2P1L1 III clear - - - - NG
20 1215 23 Primi III turbid - - - - NG
21 332 22 G2P1L1 II clear - + - - NG
22 868 22 G2P1L1 III clear - - - + NG
23 1206 24 G2P1L1 III clear - - - - NG
24 1239 18 Primi II clear - - - - NG
25 5574 30 G2P1L1 II turbid - - - - NG
26 3308 22 Primi II clear - - - - NG
27 1227 25 Primi II clear + - - + NG
28 1229 29 G3P2L2 II clear - - - - NG
29 883 25 G2P1L1 II clear - - - - NG
30 1239 28 G2P1L1 III clear - - - - NG
31 1821 26 Primi II turbid + + + - Klebsiella pneumoniae + + R S R S S S S S S S S S S
32 1165 23 G2P1L1 III clear - - - - NG
33 984 20 Primi II clear - - - - NG
34 539 25 G2P1L1 III clear - - - - NG
35 1340 21 Primi II clear - - - + NG
36 143 24 G2P1L1 III clear - - - - NG
37 1338 25 G3P1L1A1 I clear - - - + NG
38 6058 25 Primi III clear - - - - NG
39 1263 21 Primi II clear - - - - NG
40 1372 28 G2P1L1 III clear + + - +  Pseudomonas aeruginosa + + S S R S R R S S S S
41 786 28 G2P1L1 III clear - - - - NG
42 1380 23 G4P3L3 III clear + - - - NG
43 671 22 G2p1L0 II clear - - - - NG
44 1381 22 G2P1L1 II clear - - - - NG
45 1379 21 G2PILI III turbid - - - - NG
46 671 29 Primi III clear - - - - NG
47 1246 25 G3PoLoA2 II clear - - - - NG
48 1324 26 Primi III turbid - - - - NG
49 1370 22 Primi I clear - - - - NG
50 292 38 G4P2L2A1 II clear - - - - NG
51 1275 28 G2P1L1 II clear - - - + NG
52 2450 24 Primi III clear - - - - NG
53 332 22 G2P1l1 III turbid + + - + Staphylococcus aureus + + + + + + R S S S S S R S S S S S
54 1432 29 Primi III clear - - - - NG
55 1406 20 Primi III clear + - - - NG
56 2367 21 Primi III clear + + + - Escherichia coli + + + S S S S S S S S R S S S S
57 1965 32 G4P3A2L1 III clear - - - - NG
58 2134 24 G2P1L1 III clear - - - + NG
59 2458 25 Primi III clear - - - - NG
60 2459 27 Primi I clear - - - - NG
61 2456 22 Primi III clear - - - + NG
62 3488 23 Primi III clear - - - - NG
63 2980 23 Primi III clear - - - - NG
64 241 23 G2P1L1 III clear - - - - NG
65 2338 22 Primi III clear - - - - NG
66 842 31 G2P1L1 III clear - - - - NG
67 2540 25 G3P2L2 III clear + + + - Escherichia coli + + S S S S S R S S R S R S S
68 425 24 G3P2L1 III clear - - - - NG
69 1046 30 G2P1L1 III clear - - - - NG
70 2559 23 Primi III clear - + - - NG
71 2560 22 Primi III clear - - - - NG
72 274 25 G2P1L1 II clear - - - + NG
73 1464 25 Primi II clear + - - - NG
74 1353 26 Primi I turbid - - - - NG
75 4589 25 Primi II clear - - - - NG
76 1362 32 G2P1L1 III clear - - - - NG
77 1786 21 G3P2L2 III clear - - - - NG
78 1142 34 Primi III clear - - - - NG
79 421 21 Primi I clear - - - - NG
80 2312 31 Primi II clear - - - + NG
81 1713 20 G2P1L1 II clear + - - - NG
82 2523 24 G2P0L0A1 II clear - - - - NG
83 1217 27 G3P2L2 II clear - - - - NG
84 2712 29 Primi II clear - - - - NG
85 1116 18 G2P1L1 III clear - - - - NG
86 423 28 G3P0L0A2 I turbid + - + + Escherichia coli R S R S S R R R R S S S S
87 2132 18 Primi II clear - - - - NG
88 1129 27 Primi I clear - - - - NG
89 829 24 G2P1L1 II clear - - - - NG
90 525 21 G2P0L0A1 III clear - - - - NG
91 323 26 PRIMI III clear - + - - NG
92 1232 25 G2P1L1 II clear - - - - NG
93 1118 23 Primi II clear - - + - NG
94 3142 20 G2P1L1 II clear + - - - NG
95 2231 19 Primi II clear - - - - NG
96 1436 26 G3P2L2 III clear - + - - NG
97 1217 26 Primi I clear - - - - NG
98 2541 22 G2P1L1 II clear - - - - NG
99 2330 20 Primi II clear - - - - NG
100 2117 19 Primi II turbid - - - - NG
101 3164 27 Primi III turbid - - - - NG
102 3163 20 Primi III clear - - - - NG
103 3144 23 Primi  II clear - - - - NG
104 3161 28 G2P1L1 III clear - - - - NG
105 3165 20 G2P1L1 II clear - - - - NG
106 843 23 Primi II turbid + - + - Escherichia coli + + + S S S S S S S S S S S S S
107 3166 29 G2P1L1 III clear - - - - NG
108 933 24 G2P1L0 II clear - - - - NG
109 2371 30 Primi III clear - - - - NG
110 967 19 Primi II clear + - - - NG
111 2127 25 G2P1L1 I clear - - - - NG
112 3153 25 Primi III clear - - - - NG
113 2424 23 Primi III clear - - - - NG
114 3177 21 Primi II clear - - - - NG
115 2315 25 G2P1L1 I clear - - - - NG
116 3176 21 Primi III clear - - - - NG
117 1559 22 G2P1L1 III clear - - - - NG
118 660 24 G3P2L1A0 II clear - - - - NG
119 378 23 G3P2L2 III clear - - - - NG
120 2247 22 Primi III clear - - - - NG
121 1780 22 Primi III clear - - - - NG
122 2219 30 G2P1L1 II clear - + - - NG
123 2418 27 G2P1L1 II clear + + + + Pseudomonas aeruginosa + + S S S S R S S R S S
124 2457 23 Primi III clear - - - - NG
125 2569 23 G2P1L1 III clear - - - - NG
126 3795 29 G2P1L1 III clear + - + - Klebsiella pneumoniae + S R S S S S R R R R R S S
127 3338 26 G2P1L1 III clear - - - - NG
128 4310 27 G2P1L1 III clear - - - + NG
129 1420 25 G2P1L1 III clear - - - - NG
130 1299 24 G3P2L1 III clear - - - - NG
131 2243 23 G2P1L1 III turbid + + + - Klebsiella pneumoniae + S S R S S S S S R S S S S
132 2677 22 G2P1L1 III turbid + + - - Staphylococcus aureus + + + + + + R S S S R S S R S R S S
133 3320 26 G2P1L1 III clear - - - - NG
134 2499 29 G3P2L2 III clear - - - - NG
135 2567 22 Primi II clear + - - - NG
136 3108 27 Primi III turbid - - - - NG
137 2571 37 G3P1L1A1 III clear - - - + NG
138 1431 21 G2P1L1 II clear - - - - NG
139 4571 24 G2P1L1 III clear - - - - NG
140 3210 22 Primi III clear - - - - NG
141 3342 23 G2P1L1 III clear - - - - NG
142 2189 22 Primi III clear - - - - NG
143 3409 26 G2P1L1 II clear - - - - NG
144 4310 24 G2P1L1 III clear - - - - NG
145 3570 25 G2P1L1 III clear - - - - NG
146 4313 26 Primi II clear - - - - NG
147 2139 26 Primi II clear - - - - NG
148 1268 30 Primi III clear - - - - NG
149 3299 32 G3P2L2 II clear - - - - NG
150 1350 19 Primi I clear - - - - NG
151 2370 27 Primi III clear - - + - NG
152 3236 21 Primi III clear - - - - NG
153 3157 27 G2P1L1 III clear - - - - NG
154 2471 24 Primi III turbid + + + + Staphylococcus aureus + + + + + + R S R R S R R S S R S S
155 1623 22 Primi III clear - - - - NG
156 2231 25 G2P1L1 III clear - - - - NG
157 326 23 Primi III turbid + - + - Escherichia coli + + + R S S R R S S S S S S S S ESBL
158 2162 20 G2P1L1 I clear - - - - NG
159 2179 27 Primi II clear - - - - NG
160 4691 31 G2P1L1 I clear - - - - NG
161 3239 20 Primi II clear + - - - NG
162 1542 19 Primi II clear - - - - NG
163 3241 25 Primi I clear - - - - NG
164 906 28 Primi II clear - - - - NG
165 3235 23 Primi II clear - - - - NG
166 3243 25 G2P1L1 II clear - - - - NG
167 3242 19 Primi II clear - - - - NG
168 3225 25 Primi I clear + + - - Staphylococcus aureus + + + + + + R S R S S R R S S S S S
169 2389 22 G2P1L1 I clear - - - - NG
170 1398 19 Primi I clear - - - - NG
171 2985 22 G2P1L1 I clear - - - - NG
172 4431 20 Primi I clear + + + +   Staphylococcus saprophyticus + S S S S S S R S S S S S
173 3233 24 G3P1L1A1 II clear - - - - NG
174 3512 27 G2P1L1 III clear - - - - NG
175 2500 19 Primi I clear - - - - NG
176 2167 25 Primi III clear - - - - NG
177 7175 24 G3P2L2 III clear - - - - NG
178 3152 21 Primi III clear - - - - NG
179 3290 26 G2P1L1 III clear - - - - NG
180 2078 24 G2P1L1 I clear - - - - NG
181 5680 23 G2P1L1 III turbid + + + - Escherichia coli + S S S S S S S R S S R S S
182 2109 20 Primi II clear - - - - NG
183 3412 20 Primi III clear - - - - NG
184 5610 28 G2P1l1 III clear - - - - NG
185 2168 27 Primi III clear - - - - NG
186 1157 21 Primi III clear - - - - NG
187 2095 29 G2P1l1 III clear + + + + Escherichia coli + + S S R S S S S S R S S S S
188 2150 24 G2P1l1 III clear - - - - NG
189 1879 24 G2P1l1 III clear - - - - NG
190 1753 21 G2P1l1 III clear - - - + NG
191 1849 20 G2P1l1 III clear - - - - NG
192 1597 25 Primi III clear + + - + Klebsiella pneumoniae + + S S R S S S S R S S S S S
193 2156 28 G2P1l1 III clear - - - - NG
194 2164 19 Primi I clear - - - - NG
195 1054 21 G2P1l1 II clear - - - - NG
196 3210 30 G2P1L1 II clear - - - - NG
197 2241 22 G3P2L2 II clear - - - - NG
198 2154 28 Primi III clear - - - - NG
199 1742 28 Primi II clear - - - - NG
200 1748 37 G3P2L2 III clear - - - - NG
201 4532 23 G2P1L1 II clear + - - - NG
202 2139 22 G2P1L1 II clear - - - - NG
203 4509 23 Primi III clear - - - - NG
204 3217 19 Primi III clear - - - - NG
205 4446 26 G2P1L1 II clear - - - - NG
206 3489 29 G2P1L1 I clear - - - - NG
207 3399 20 Primi III clear - - - - NG
208 4410 28 G2P1L1 II clear - - - - NG
209 5217 29 G6A5 III clear - - - - NG
210 2970 30 Primi II turbid + - - - Staphylococcus aureus + + + + + + R S R S R S R R R R S S
211 4088 23 Primi II clear - - - - NG
212 2468 23 G2P1L1 I clear - - - - NG
213 3371 21 G2P1L1 III clear - - - - NG
214 1882 25 Primi II clear - - - - NG
215 3502 28 G4A3 II clear + + + - Staphylococcus aureus + + + + + + R S S R S S S S S S S S
216 3507 22 G2P1L1 III clear - - - - NG
217 3511 25 G3P2L2 III clear - - - - NG
218 3505 28 G2P1L1 II clear - - - - NG
219 3509 25 G2P1L1 III clear - - - - NG
220 3510 25 G2P1L1 III clear - - - - NG
221 2903 24 Primi III clear - - - - NG
222 3508 23 G3P1L1A1 II clear - - - - NG
223 3495 20 Primi III clear - - - - NG
224 3068 27 G3P1L1A1 I clear - - - - NG
225 3294 26 G3P2L2 II clear + + + - Klebsiella pneumoniae + R R R S S R R R S S R S S
226 3490 33 G4P1L1A2 II clear - - - - NG
227 2997 28 Primi II clear - - - - NG
228 3496 21 G2P1L1 II clear - - - - NG
229 3512 24 G2P1L1 II clear - - - - NG
230 2813 29 G2P1L1 II clear - - - - NG
231 3308 23 G3P1L1A1 II turbid + + + + Klebsiella pneumoniae + S S R R R R S S R S R S S ESBL
232 1551 27 G3P2L2 II clear - - - - NG
233 1555 20 Primi III turbid + - + + Escherichia coli + + R S S S S S S S S S S S S
234 2341 24 G2P1L1 II clear + - - - NG
235 2690 21 Primi III clear - - - - NG
236 1665 23 G2P1l1 II clear - - - - NG
237 3287 25 G3P2L2 III clear - - - - NG
238 3307 23 G2P1l1 III turbid + - - + Staphylococcus aureus + + + + + + + R S R S R S S R S R S S
239 4411 30 G2P1L1 III clear - - - - NG
240 4321 28 Primi II clear - - - - NG
241 3492 20 Primi II clear - - - - NG
242 1195 24 Primi III clear - - - - NG
243 1667 21 Primi II turbid - - - - NG
244 2351 25 G2P1L1 II clear - - - - NG
245 2247 22 Primi III clear - - - - NG
246 3846 21 Primi III clear - - - - NG
247 3506 27 G2P1L1 III clear - - - - NG
248 3838 24 Primi I clear - - - - NG
249 3840 25 G2P1L1 III clear - - - - NG
250 2439 24 Primi II turbid + + + - Escherichia coli + + S S S S S R S R S S R S S
251 3849 24 G2P1L1 III clear - - - - NG
252 3593 20 Primi II clear + - - - NG
253 3593 23 Primi III turbid - - - - NG
254 2940 28 Primi II clear - - - - NG
255 3821 23 Primi I clear - - - - NG
256 3650 28 G2P1L1 III clear - - - - NG
257 618 21 Primi III clear - - - - NG
258 2571 29 Primi III clear - - - - NG
259 3851 22 G2P1L1 II clear - - - - NG
260 3601 23 G3P1L1A1 II clear + + + + Staphylococcus aureus + + + + + + R S S S S S R S S R S S
261 3866 25 G2P1L1 III clear - - - - NG
262 3867 23 Primi II clear - - - - NG
263 3200 28 Primi III clear - - - - NG
264 3533 21 G2P1L1 I clear - - - - NG
265 3670 27 G3P1L1A1 I clear - - - - NG
266 2960 26 G2P1L1 I clear - - - - NG
267 3217 24 Primi II clear - - - - NG
268 4559 24 Primi I clear - - - + NG
269 3859 26 Primi I turbid - - - - NG
270 2299 20 G2P1L1 II clear - - - - NG
271 2588 23 Primi III clear - + - - NG
272 3864 24 Primi III turbid + + - + Pseudomonas aeruginosa + + + R S R S S R R S S S
273 1868 29 G4P1L1A2 II clear - - - - NG
274 8863 23 Primi II clear - - - - NG
275 3316 21 Primi II clear - - - - NG
276 4100 22 G2P1L1 III clear - - - - NG
277 3460 30 G3P2L2 III clear - - - - NG
278 3004 25 G2P1L1 III clear - - - - NG
279 8374 19 Primi I clear - - - - NG
280 3311 20 Primi III clear - - - + NG
281 3812 20 Primi II clear - - - - NG
282 2368 27 G2P1L1 II clear - - - - NG
283 2778 22 G2P1L1 III clear + - + - Escherichia coli + + S S S S S R S S R S S S S
284 3372 23 G2P1L1 II clear - - - - NG
285 314 20 Primi II clear - - - - NG
286 3335 24 Primi I clear - - - - NG
287 2921 25 G3P1L1A1 II clear - - - - NG
288 1676 26 Primi II turbid + - - - NG
289 3036 25 G2P1L1 II clear - - - - NG
290 3486 29 G2P1L1 II clear - - - - NG
291 1825 29 G2P1L1 III clear - - - + NG
292 2221 21 Primi II clear - - + - NG
293 1049 21 Primi II clear - - - - NG
294 1419 22 Primi III clear - - - - NG
295 1542 18 Primi I clear - - - - NG
296 3952 24 G2P1L1 II clear + + - + Enterococcus faecalis + S S S S S S S S S
297 3948 24 G2P1L1 I clear - - - - NG
298 3947 21 G2P1L1 III clear - - - - NG
299 2781 26 Primi III clear - - - + NG S S
300 3954 24 G2P1L1 III clear - - - - NG
301 3050 26 G2P1L1 III clear - - - - NG
302 2662 22 Primi III clear - - - - NG
303 707 20 Primi I clear - - - - NG
304 3955 28 G2P1L1 III clear - - - - NG
305 3950 27 G2P1L1 II clear + - - - NG
306 3958 26 G2P1L1 II clear - - - - NG
307 3956 26 G2P1L1 II clear - - - - NG
308 3813 22 G2P1L1 I clear - - - - NG
309 3009 24 G2P1L1 II clear - - - - NG
310 3954 20 Primi I clear + + + - Escherichia coli + R S S S S S R R S S S S S
311 8590 19 Primi III clear - - - - NG
312 2155 28 G2P1L1 II clear - - - - NG
313 6018 29 G3P1L1A1 II clear - - - - NG
314 8451 31 Primi II clear - - - - NG
315 8481 35 G3P2L2 III clear - - - - NG
316 3638 29 G2P1L1 I clear - - - - NG
317 3273 19 Primi I turbid - - - - NG
318 7633 30 G2P1L1 III clear - - - - NG
319 4165 33 G2P1L1 II clear - - - - NG
320 4160 26 G2P1L1 III clear - - - - NG
321 2813 22 Primi III clear - - - - NG
322 4166 22 Primi II clear - - - - NG
323 2183 23 G2P1L1 II clear + - - - NG
324 2661 20 Primi III turbid + + - + Staphylococcus aureus + + + + + + + R S R R S S S R R S S S
325 3113 29 G2P1L1 II clear - - - - NG
326 4073 27 G2P1L1 II clear - - - - NG
327 4164 24 Primi III clear - - - - NG
328 4151 27 G2P1L1 II clear - - - - NG
329 4113 25 G2P1L1 II clear - - - - NG
330 1184 22 G2P1L1 III clear - - - - NG
331 2353 23 Primi II clear - - - - NG
332 934 24 G2P1L1 II turbid - - - - NG
333 6822 33 G2P1L1 II clear + - - - Staphylococcus aureus + + + + + R S S S S R R S S R S S
334 4168 23 G3p2l2 I clear + + + - Escherichia coli + + S S S S S S S S R S S S S
335 2864 23 G2P1L1 II clear - - - - NG
336 4169 20 G2P1L1 II clear - - - - NG
337 8877 20 Primi I clear - - - - NG
338 6984 19 Primi I clear - - - - NG
339 4137 24 G2P1L1 III clear - - - - NG
340 4138 33 G3P2L2 III clear - - - - NG
341 7175 24 Primi I clear - - - - NG
342 2040 23 Primi II clear - - - - NG
343 4050 18 Primi I clear + + + - Klebsiella pneumoniae + S S S S S S S S S S S S S
344 6943 31 G2P1L1 III clear + - - - NG
345 4043 21 Primi I clear - - - - NG
346 4142 19 Primi II clear - - - - NG
347 4144 25 G2P0L0A1 II clear - - - - NG
348 2500 19 Primi II clear - - - - NG
349 1542 18 Primi II turbid + + + + Escherichia coli + + S S R S S R S R R S R S S
350 4436 27 G2p1L1 III clear - - - - NG
351 3292 28 G2P0L0A1 I clear - - - - NG
352 3015 23 Primi II clear - - - - NG
353 4170 20 G2P1L1 II clear - - - - NG
354 4171 23 Primi II clear - - - - NG
355 3422 22 Primi II clear - - - - NG
356 2891 24 G2P1L1 II clear - - - - NG
357 4184 25 Primi II clear - - - - NG
358 2765 21 G2P1L1 III clear - - - - NG
359 2756 28 G2P1L1 III clear - - - - NG
360 1956 23 Primi II clear - - - - NG
361 2367 21 Primi III clear - - - - NG
362 996 32 G2P1L1 III clear - - - - NG
363 4180 30 Primi II turbid - - - - NG
364 3331 30 G2P1L1 II clear - - - - NG
365 4179 34 G2P1L1 III clear - - - - NG
366 1332 29 G2P1L1 III clear - - - - NG
367 4178 29 G3P2L2 I clear + - + + Proteus mirabilis + + + R S R S S R R R R S R S S
368 3412 20 Primi II clear - - - - NG
369 2376 27 G3P2L1 III clear - - - - NG
370 4185 20 Primi III clear + - - - NG
371 3424 26 G2P1L1 I clear - - - - NG
372 1211 20 Primi III clear - - - - NG
373 2975 23 Primi III turbid - - - - NG
374 2781 23 Primi II clear - - - - NG
375 4094 23 G2P1L1 II clear - - - - NG
376 1698 25 G3P2L1 II clear - - + - NG
377 8945 20 G2P1L1 I clear - - - - NG
378 4187 24 G3P2L2 II clear - - - - NG
379 4233 21 Primi II clear - - - - NG
380 3581 26 G2P1L1 I clear - - - - NG
381 3623 23 Primi I clear - - - - NG
382 2891 31 G3P2L2 III clear - - - - NG
383 2342 26 G2P1L1 II clear - - - - NG
384 3355 20 Primi I clear - - - - NG
385 3983 24 Primi II clear - - - - NG
386 3128 22 G2P1L1 I clear - - - - NG
387 3319 31 G2P1L1 II clear - - - - NG
388 2183 29 Primi III clear - - - - NG
389 3390 31 G3P1L1A1 I clear + + + + Klebsiella pneumoniae + R R R R R S S S R S S S S ESBL
390 4496 20 Primi I turbid + + + - Escherichia coli + + R S S S S S S S S S S S S
391 3056 23 G2P1L1 II clear - - - - NG
392 10293 31 G2P1L1 II clear + - - - NG
393 4210 25 Primi III clear - - - - NG
394 3074 25 Primi I clear - - - - NG
395 4211 26 Primi II turbid - - - - NG
396 4217 31 G3P2L2 II clear + + + +  Staphylococcus saprophyticus + S S S S S S R R S R S S
397 2299 27 Primi III clear - - - - NG
398 3457 19 Primi II clear - - - - NG
399 2199 18 Primi I clear - - - - NG
400 5318 23 G2P1L1 III clear - - - + NG
401 3866 26 G2P1L1 II clear - - - - NG
402 3996 25 Primi III clear - + + + Escherichia coli S S R S S S R R S S S S S
403 4658 22 Primi III clear - - - - NG
404 3988 32 Primi III clear - - - - NG
405 4661 26 G2P1L1 III clear - - - - NG
406 2951 25 Primi II clear - - - - NG
407 3622 20 G2P1L1 III clear - - - - NG
408 4652 20 Primi III clear - - - - NG
409 3990 30 G3P2L1 III clear - - - - NG
410 3654 27 G2P1L1 II clear - - - - NG
411 4653 18 Primi I clear + + - - Escherichia coli + + + S S S S S S S S R S S S S
412 4659 28 Primi II clear - - - - NG
413 3639 20 Primi III clear - - - - NG
414 4663 35 G3P2L2 II clear - - - - NG
415 4662 25 G2P1L1 III clear - - - - NG
416 2618 23 G2P1L1 I clear - - - - NG
417 9805 21 G2P1L1 I clear - - - - NG
418 1465 26 Primi III turbid - - - - NG
419 4642 21 G3P0L0A2 II turbid - - - - NG
420 4562 27 Primi III clear + - - - NG
421 4561 31 G2P1L1 I clear - - - - NG
422 4573 21 G2P0L0A1 I clear - - - - NG
423 4565 24 G2P1L1 II clear - - - - NG
424 9630 25 G2P1L1 II clear - - + - Klebsiella pneumoniae + R R R S S R S R S R S S S
425 1430 20 Primi II clear - - - - NG
426 6522 29 G3P2L2 III clear - - - - NG
427 4618 19 Primi I clear - - - - NG
428 4412 25 G3P1L1A1 II clear - - - - NG
429 4700 21 Primi I clear - - - - NG
430 4621 23 Primi II clear - - - - NG
431 2561 25 G2P1L1 II clear + + - + Staphylococcus aureus + + + + + + + R S R S R S R R S R S S
432 4081 26 G3P1L1A1 III clear - - - - NG
433 1626 29 G3P2L2 III clear - - - - NG
434 3653 31 G2P1L1 II clear - - + + Escherichia coli + R S S S S S S S S S S S S
435 4073 30 Primi III clear - - - - NG
436 4629 28 G2P1L1 I clear - - - + NG
437 9686 22 Primi I clear - - - - NG
438 4393 25 G2P1L1 II clear - - - - NG
439 3854 27 G2P1L1 II clear + - - - NG
440 4632 21 Primi I clear - - - - NG
441 4576 19 Primi I clear - - - - NG
442 4093 26 G2P1L1 II clear - - - - NG
443 3574 27 G3P2L2 II clear - - - - NG
444 2897 23 PRIMI I clear - - + - NG
445 1492 20 Primi I turbid - - - - NG
446 3207 21 Primi III clear - - - - NG
447 3335 23 Primi II clear + + + - Enterococcus faecalis + S S R S R S S R S
448 2287 27 G2PILI II clear - - - - NG
449 4512 24 G2PILI III clear - - - - NG
450 1299 28 G3PILIAI I clear - - - + NG
451 3277 25 PRIMI II clear - - - - NG
452 2265 29 G3P2L2 II clear - - - - NG
453 3276 30 G4P2L2A1 III clear - - - - NG
454 5471 24 Primi I clear - - - - NG
455 5291 28 G2P1L1 II clear - - - + NG
456 5342 26 G2P1L1 II clear - - - - NG
457 1099 27 G2P1L1 III clear - - - - NG
458 1567 23 Primi II clear - - - - NG
459 5897 25 Primi I clear - - - - NG
460 3492 23 Primi I clear + - - - NG
461 3386 22 Primi II clear - - - - NG
462 1906 25 G2P1L1 III clear - - - - NG
463 1789 32 G3P2L2 II clear - - - - NG
464 1654 22 Primi I clear - - - - NG
465 3254 18 Primi II turbid - - - - NG
466 4467 21 Primi III clear - - - - NG
467 1556 21 Primi III turbid - - - - NG
468 1543 24 G2P1L1 I clear - - - - NG
469 3330 20 Primi II clear - - - - NG
470 2431 23 G2P1L1 I clear - - - - NG
471 4657 30 G3P2L2 III clear - - - - NG
472 3338 27 G3P0L0A2 III clear - - - - NG
473 1673 24 Primi I clear - - - - NG
474 1324 24 Primi I turbid - + - + Klebsiella pneumoniae + R R S S S S R S S R R S S
475 1783 24 G2P1L1 II clear + - - - NG
476 2156 27 G2P1L1 II clear - - - - NG
477 3578 28 G3P2L2 III clear - - - - NG
478 3321 29 Primi I clear - - - - NG
479 5623 25 Primi I clear - - - - NG
480 1054 22 Primi II clear - - - - NG
481 1056 25 Primi II clear - - - - NG
482 1059 26 G2P1L1 III clear - - - - NG
483 4499 27 G2P1L1 III clear - - - - NG
484 2143 26 G2P1L1 III clear - - - - NG
485 5498 28 G2P1L1 II turbid + + + + Proteus mirabilis + + R R R S S S R S S R S S S
486 4091 27 Primi III clear - - - - NG
487 3358 19 Primi III clear - - - - NG
488 2365 19 Primi III clear - - - - NG
489 2109 23 G2P0L0A1 I clear - - - - NG
490 3256 27 G3P0L0A2 II clear - - - - NG
491 2190 23 Primi II clear - - - - NG
492 3091 24 Primi II clear - - - - NG
493 5632 22 Primi III clear + - - - NG
494 3330 21 Primi I clear - - - - NG
495 2274 24 G2PILI II clear - - + - NG
496 3219 24 G2P1L1 I clear - - - - NG
497 5318 27 Primi II turbid + + + + Klebsiella pneumoniae + R R R S S S R R S S S S S
498 2221 33 G3P1LIA1 III clear - - - - NG
499 3980 22 Primi II clear - - - - NG
500 3465 23 Primi I clear - - - - NG
501 6574 32 G2P1L1 II clear - - - - NG
502 6788 22 Primi III turbid - - - - NG
503 2280 28 G2P1L1 I clear - - - - NG
504 6789 20 Primi II clear - - - - NG
505 6790 23 Primi I clear - + + + Klebsiella pneumoniae + + R S R S S S S S R R R S S
506 6795 21 Primi III clear - - - - NG
507 2522 19 Primi II clear - + - -    Staphylococcus saprophyticus R S S S S S S R S S S S
508 4388 25 G2P1L1 I clear - - - - NG
509 5781 25 G2P1L1 I clear + + + + Klebsiella pneumoniae + R R R S S S S R S S S S S
510 5558 19 Primi I clear - + + + Escherichia coli + S S R S S S S R R S S S S
511 4217 24 G2P1L1 III clear - - - - NG
512 5670 28 G2P1L1 I turbid + + + + Escherichia coli + S S S S S S S R S S R S S
513 5099 20 Primi II turbid - - - - NG
514 3195 20 Primi II clear + - - - NG
515 2108 20 G2P1L1 III clear - - - - NG
516 10164 22 Primi II clear - - - - NG
517 6432 18 Primi II turbid - + + + Escherichia coli + R S R S S S S R S S S S S
518 6779 24 Primi I clear - - - - NG
519 9856 23 G2P1L1 III clear - - - - NG
520 4320 18 Primi I turbid + - + + Staphylococcus aureus + + + + + + + S S S S S R R S S S S S
521 5570 21 Primi II clear - - - - NG
522 5007 24 G2PILI III clear - - - - NG
523 4488 26 G2PILI III clear - - - - NG
524 10408 39 G3P0L0A2 III clear - + - - Enterococcus faecalis + R S S S S S S R S
525 3242 18 Primi I clear - - - - NG
526 6622 23 Primi I clear - - - - NG
527 7890 20 Primi II clear - - - - NG
528 4529 29 G2PILI III clear - - - - NG
529 4522 27 G2PILI II clear - - - - NG
530 3211 19 Primi II clear - - - - NG
531 3399 21 Primi I clear - + - + Enterococcus faecalis + R R S R R R S S S
532 5679 20 Primi I clear - - - - NG
533 1092 25 G2PILI II clear - - - - NG
534 10431 18 Primi I turbid - - - - NG
535 4567 27 G2PILI II clear - - - - NG
536 1299 24 Primi III clear - - - - NG
537 4490 19 Primi I clear - - - - NG
538 3597 20 Primi II turbid + + + +    Staphylococcus saprophyticus S S R S S S S S S S S S
539 2188 23 Primi II clear - - + - NG
540 4869 21 Primi II clear - - - - NG
541 12309 25 G3P2L2 III clear - - + - Klebsiella pneumoniae + R S S S S S S S R R S S S
542 23450 37 G2PILI II clear - - - - NG
543 35621 26 G2PILI I clear + - - - NG
544 3339 22 Primi II clear - - - - NG
545 3677 21 Primi II clear - - - - NG
546 3680 35 G3P2L2 III clear - - - + NG
547 3677 26 Primi I clear - - - - NG
548 5682 25 G2PILI II clear - - - - NG
549 23488 25 G2PILI I turbid + + + + Escherichia coli S S R S S R S S R S R S S ESBL
550 56799 25 Primi II clear - - - - NG
551 1785 21 Primi III turbid - - - - NG
552 4168 18 Primi I turbid - - - - NG
553 4359 20 Primi II turbid + + + + Escherichia coli + + S S S S S S S S S S R S S
554 5428 21 G2PILI III clear - - - - NG
555 4677 22 Primi I clear - - - - NG
556 5536 25 Primi II clear - - - - NG
557 5271 26 G2PILI I clear - - - - NG
558 5672 20 Primi III clear - - - - NG
559 43109 23 G3P0L0A2 I clear + + + + Escherichia coli S S S S S S R R S S S S S
560 3579 20 Primi I clear - - - - NG
561 4486 19 Primi II clear - - - - NG
562 2409 21 G2PILI II clear - - - - NG
563 5334 27 G2PILI III clear - - - - NG
564 5431 30 G2P0L0A1 I clear - - - - NG
565 4828 30 G2PILI II clear - - - - NG
566 5532 28 G2PILI II turbid - - - - NG
567 5531 20 Primi I clear - - - + Staphylococcus aureus + + + + + + S S R R S S R R S R S S
568 5530 27 Primi II turbid - - - - NG
569 23688 25 Primi I turbid + - - - NG
570 5529 26 G2PILI I turbid - - - - NG
571 5528 22 Primi II clear - + - - NG
572 3004 25 Primi II clear - + + + Klebsiella pneumoniae + S S S S S R S R S S R S S
573 3012 23 G2PILI III clear - - - - NG
574 3197 22 Primi II clear - - - - NG
575 11225 20 Primi I clear - - - - NG
576 1209 19 Primi II clear - - - - NG
577 2303 19 Primi I turbid + - + - NG
578 5262 18 Primi I turbid - - - - NG
579 4132 23 Primi III clear - - - - NG
580 18873 23 G2PILI III clear - - - - NG
581 5397 25 G2PILI II clear - - - - NG
582 5505 27 G3P2L2 II clear - - - - NG
583 11339 21 Primi III clear - - - - NG
584 11335 20 Primi II clear + + + + Enterococcus faecalis S S S S S R S R S
585 11224 18 Primi I clear - - - - NG
586 11340 25 G2PILI I clear - - - - NG
587 5791 23 Primi I clear - - - - NG
588 47901 27 Primi III clear - - - - NG
589 5132 29 G2P0L0A1 I clear - - - - NG
590 4030 30 G3P2L2 I clear - + + - Escherichia coli + + R S R S S S S S S R S S S
591 11227 31 Primi II turbid - - - - NG
592 5512 20 Primi I clear - - - - NG
593 5516 19 Primi I clear - - - - NG
594 6037 25 G2PILI II clear - - - - NG
595 2292 26 G2PILI III clear - + + + Escherichia coli + S S S S S R S R S S S S S
596 2217 23 G2PILI I clear - - - - NG
597 5032 22 Primi I clear - - - - NG
598 23864 20 Primi I turbid - - - + NG
599 4684 30 G2PILI I clear - - - - NG
600 5519 19 Primi I turbid + + + + Klebsiella pneumoniae + R R R S S S S S R S R S S
601 5809 23 Primi II clear - - - - NG
602 5177 27 Primi II clear - - - - NG
603 15690 24 G2PILI III clear - - - - NG
604 1451 26 G3P2L2 III clear - - - - NG
605 5518 20 Primi II clear - - - - NG
606 3036 21 Primi II clear - - - - NG
607 6982 23 Primi I clear - - - - NG
608 11464 25 Primi I clear - - - - NG
609 11458 27 G2PILI III clear - - - - NG
610 5668 22 Primi II turbid - - - + NG
611 20981 29 G3P2L2 II clear - - - - NG
612 1779 21 Primi I turbid - - - - NG
613 1256 20 Primi I clear - - - - NG
614 1890 21 G2PILI II clear - + - +   Staphylococcus saprophyticus R S S R S S R S S S S S
615 3299 23 Primi I clear - - - - NG
616 5541 25 G2PILI I turbid - + + + Escherichia coli + + S S S S S S S S R S S S S
617 5839 24 G3P0L0A2 I clear - - - - NG
618 21090 21 Primi II clear - - - - NG
619 46732 22 Primi II clear - - - - NG
620 24581 28 G2PILI I clear - - - - NG
621 27903 24 Primi III clear - - - - NG
622 22675 19 Primi I turbid - + - - Staphylococcus aureus + + + + + + S S R R S S S S S S S S
623 8432 23 G2PILI II clear - - - - NG
624 5742 32 G2PILI I clear - - - - NG
625 3215 19 Primi II clear - - - - NG
626 22210 23 Primi II clear - + + + Escherichia coli R R R S S S S R R S R S S
627 1639 29 G3PIL2 I clear - + + + Escherichia coli R S S S S S S S S S S S S
628 14690 27 G2P1L1 III clear - - - - NG
629 11488 24 Primi I clear - - - - NG
630 11505 29 G2PILI I clear - + - + Staphylococcus aureus + + + + + + S S S S R S R R S S S S
631 3661 28 Primi III clear - - - - NG
632 21998 20 Primi III turbid - - + - Klebsiella pneumoniae + R R R S S S S S R S S S S
633 2599 32 G2PILI II clear - - - - NG
634 11506 24 Primi I turbid - - - - NG
635 54399 23 Primi I clear - - - - NG
636 32100 21 Primi II clear - - - - NG
637 7634 22 Primi II clear - - - - NG
638 1991 25 Primi III clear - - - - NG
639 5392 21 G2PILI II clear - - - - NG
640 3714 27 G2PIL1 II clear - - - - NG
641 5285 27 Primi III clear - - - - NG
642 5490 29 G2P0L0A1 I clear - - - - NG
643 21790 30 G2PILI I clear - - - - NG
644 4329 22 Primi I clear - - - - NG
645 4644 35 G3PILIA1 II turbid - - - - NG
646 2155 19 Primi III clear - - - - NG
647 2380 19 Primi I clear - - - - NG
648 2161 24 G2PILI II turbid - - - - NG
649 2700 20 Primi II turbid - + + - Escherichia coli + R S S S S S S R S S R S S
650 5629 24 Primi I clear - - - - NG
651 11076 35 G3PILIA1 III clear - - - - NG
652 22109 23 G2PILI II clear - - - - NG
653 2196 32 G2PILI III clear - - - - NG
654 2387 26 G2P1L1 II clear - - - - NG
655 10902 30 G2P0L0A1 I clear - - - - NG
656 5620 24 G2PILI II clear - + + +     Staphylococcus saprophyticus S S S S R S S R S S S S
657 3218 23 Primi I clear - - - - NG
658 2166 23 Primi I clear - - - - NG
659 1E+05 21 Primi I clear - - - - NG
660 2136 21 Primi I turbid + + + + Escherichia coli + S S R S S S S S S S R S S
661 6781 22 Primi I clear - - - - NG
662 3491 23 G2P1L1 III clear - - - - NG
663 21891 32 G2P1L1 I clear - - - - NG
664 5427 25 Primi I clear - - - - NG
665 9563 20 Primi I clear - - - - NG
666 3999 19 Primi I clear - - - - NG
667 10524 22 G2P1L1 II clear - - - + NG
668 3288 26 G2P1L1 II turbid - - - - NG
669 8138 35 G3P2L2 II clear - - - - NG
670 6549 27 Primi I turbid + + + + Escherichia coli R R S S S S R R R S S S S
671 2556 31 G2P1L1 III clear - - - - NG
672 2275 21 G2P1L1 I clear - - - - NG
673 2381 29 G2P1L1 II clear - - - - NG
674 10978 21 Primi I clear - - - - NG
675 56546 35 G2P1L1 III turbid - - - - NG
676 10918 18 Primi I clear - - - - NG
677 5364 27 G2P1L1 II clear - + - - Staphylococcus aureus + + + + + + S S R S S S S R S R S S
678 10935 30 G2P1L1 III clear - - - - NG
679 5531 24 Primi II clear - - - - NG
680 6459 26 Primi I clear - - - - NG
681 43210 18 Primi I clear - - - - NG
682 25678 20 Primi I clear - - - - NG
683 10763 30 G2P0L0A1 II clear - - - - NG
684 4068 19 Primi I clear - - - - NG
685 1580 24 Primi III clear - - - - NG
686 4551 21 Primi II clear - - - - NG
687 4375 29 G2P1L1 I clear - - - - NG
688 3256 26 Primi III clear - - - - NG
689 4218 35 G2P1L1 III clear - - - - NG
690 3277 28 G2P1L1 III clear - - - - NG
691 3329 21 Primi I turbid - + + +    Staphylococcus saprophyticus R S R S S R S S S R S S
692 3571 27 G2P1L1 II clear - - - - NG
693 6788 30 G2P1L1 III clear - - - - NG
694 3357 29 G2P1L1 I clear - - - - NG
695 2841 26 Primi II clear - - - - NG
696 45681 22 Primi III clear - - - - NG
697 32199 28 Primi I clear - - - - NG
698 2188 22 Primi I turbid - - - - NG
699 34660 25 G2P1L1 II clear - - - - NG
700 3592 35 G3PILIA1 I clear - - - - NG
701 4255 32 G3P2L2 III turbid + - + + Escherichia coli R S S R R S S S S S S S S
702 6572 24 Primi I turbid - - - - NG
703 2190 35 G2P1L1 I clear - - - - NG
704 1E+05 37 G2P1L1 I clear - - - - NG
705 32188 20 Primi III clear - - - - NG
706 1E+05 27 G2P1L1 I clear - - - - NG
707 1E+05 30 G2P1L1 II clear - - - - NG
708 11634 35 G2P1L1 III clear - - - - NG
709 23756 30 G2P1L1 III turbid - - - - NG
710 17890 28 G2P1L1 II clear - - - - NG
711 12645 22 Primi I clear - - - - NG
712 4209 25 Primi I clear - - - - NG
713 5281 30 G2P1L1 II clear - - - - NG
714 2783 33 G3P2L1A1 III clear + + - - Escherichia coli + + R S R S S R S R S S S S S
715 45779 28 G2P1L1 I clear - - - - NG
716 37654 20 Primi I clear - - + + Escherichia coli S S S S S S S R R S S S S
717 5468 30 G2P0L0A1 III clear - - - - NG
718 11961 31 G3P2L2 II clear - - - - NG
719 2764 29 G2P1L1 I clear - - - - NG
720 9871 24 Primi I clear - - - - NG
721 3178 34 G2P1L1 III turbid - - - - NG
722 10818 32 G2P1L1 I clear - + + -    Staphylococcus saprophyticus R S R S S R S S S S S S
723 5253 27 G2P1L1 II clear - - - - NG
724 3577 21 Primi II clear - - - - NG
725 3298 33 G2P1L1 III clear - - - - NG
726 1588 25 Primi I clear - - - - NG
727 6633 22 Primi II clear - - - - NG
728 35790 21 Primi I clear - - - - NG
729 36712 22 Primi III clear - - - - NG
730 4903 23 G2P1L1 I clear - - - - NG
731 11995 38 G3P1L1AI I clear - - - - NG
732 54673 30 G2P1L1 II clear - - - - NG
733 12129 26 G2P1L1 II clear - - - - NG
734 36475 28 G2P1L1 III clear - - - - NG
735 23456 25 Primi II turbid - - + - NG
736 36361 24 Primi I turbid - - - - NG
737 5684 19 Primi I clear - + + - Klebsiella pneumoniae + R S S S S S S R R R R S S
738 24576 26 Primi I clear - - - - NG
739 2145 22 Primi I clear - - - - NG
740 34567 21 Primi III clear - - - - NG
741 24318 33 G2P1L1 II turbid - - - - NG
742 23458 20 Primi II clear - - - - NG
743 9792 29 G2P1L1 III turbid - - - - NG
744 1222 21 Primi I clear - - - - NG
745 3298 20 Primi I turbid - + + + Staphylococcus aureus + + + + + + S S R S S R R S R S S S
746 6482 27 G2P1L1 III clear - - - - NG
747 3645 24 Primi II clear - - - - NG
748 12748 22 Primi I clear - - - - NG
749 5355 30 Primi III clear - - - - NG
750 3477 29 Primi I clear - - - - NG
751 65430 27 G2P1L1 III turbid - - - - NG
752 21980 35 G2P1L1 II clear - - - - NG
753 5791 33 G2P1L1 II clear - - - - NG
754 23549 28 G2P1L1 I clear - - - - NG
755 5619 29 G2P0L0A1 I clear - - - - NG
756 3974 19 Primi I clear - - - - NG
757 5338 23 Primi II clear - - - - NG
758 2748 20 Primi I clear - - - - NG
759 12346 20 Primi I clear - - - - NG
760 32648 23 G2P1L1 III clear - - - - NG
761 64352 25 G2P1L1 II turbid + + + + Escherichia coli + R S S S S S S S S R S S S
762 32409 20 Primi I clear - - - + NG
763 4441 26 Primi III clear - - - - NG
764 5876 26 G2P1L1 II clear - + - - NG
765 53521 33 G2P1L1 II clear - - - - NG
766 3210 22 Primi I clear - - - - NG
767 54091 24 Primi II clear - - - - NG
768 23898 30 G2P1L1 III turbid - - - - NG
769 6971 30 G2P1L1 III clear - - - - NG
770 19830 24 Primi II clear - - - - NG
771 13221 30 G2P1L1 I clear - - - - NG
772 5898 29 G3P0L0A2 I clear - - - - NG
773 5891 21 Primi II clear - - - - NG
774 7639 20 Primi III turbid - - - - NG
775 12773 29 G2P1L1 II clear - - - - NG
776 5778 23 Primi III clear - - - - NG
777 23556 24 Primi I clear - - - - NG
778 23477 21 Primi I clear - - - - NG
779 21987 21 Primi I clear - - - - NG
780 34661 25 Primi II clear - - - - NG
781 3652 25 Primi III clear - - - - NG
782 32908 30 G2P1L1 II turbid - - - - NG
783 3115 23 Primi II clear - - - - NG
784 4556 25 Primi III clear - - - - NG
785 2233 23 Primi II clear + + + + Escherichia coli + + R R S S S S S R S S S S S
786 5571 39 G3P1L1AI I turbid - - - - NG
787 5011 36 G2P1L1 I clear - - - - NG
788 4590 34 G2P1L1 III clear - - - - NG
789 1890 23 Primi I clear - - - - NG
790 21775 24 Primi II clear + + + + Escherichia coli + R R R S S S S S S S R S S
791 962 32 G2P1L1 I clear - - - - NG
792 12240 31 G3P2L2 I clear - - + - NG
793 1778 23 Primi III clear - - - - NG
794 12662 21 G2P1L1 II clear - - - - NG
795 12389 25 G2P1L1 III clear - - - - NG
796 6523 19 Primi II turbid - - - - NG
797 5403 21 Primi I turbid - - - - NG
798 73420 29 G2P1L1 I clear - - - - NG
799 2563 24 Primi III clear - - - - NG
800 7770 33 G2P1L1 II clear - - - - NG
801 4714 23 Primi I clear - - - - NG
802 2506 22 Primi II clear - - - - NG
803 4935 26 G2P1L1 III clear - - - - NG
804 23465 22 Primi I clear - - - - NG
805 79091 31 G2P1L1 II turbid - - + - Escherichia coli + R S R S S S S S S S S S S
806 3278 21 Primi I clear + - - - NG
807 76412 28 Primi I clear - - - - NG
808 239 34 G2P1L1 II clear - - - - NG
809 4681 28 G2P1L1 I clear - - - - NG
810 23564 27 G2P1L1 II clear - - - - NG
811 66721 20 Primi II clear - - - - NG
812 78192 19 Primi III clear - - - - NG
813 2789 22 Primi II clear - - - - NG
814 7522 23 Primi I clear - - - - NG
815 8218 31 G2P1L1 III clear - - - - NG
816 8374 21 Primi I clear - - - - NG
817 7513 25 Primi II turbid - - - - NG
818 7310 32 G2P1L1 III clear - - - - NG
819 1224 26 Primi II turbid - - - - NG
820 5757 29 G2P1L1 III clear - - - - NG
821 2830 28 G2P1L1 II clear - - - - NG
822 13828 21 Primi I turbid - - - - NG
823 1012 24 Primi II clear - - - - NG
824 3199 23 Primi I clear - - - - NG
825 4312 22 Primi I clear - - - - NG
826 5400 24 Primi II clear - - - - NG
827 4165 22 Primi III clear - - - - NG
828 3295 26 G2P1L1 II clear - - - - NG
829 1454 18 Primi I clear - - - - NG
830 6123 20 Primi I clear - - - - NG
831 3336 26 G2P1L1 III turbid - - - - NG
832 1544 28 G2P1L1 II turbid - - - - NG
833 8611 25 Primi I clear - + + +    Staphylococcus saprophyticus S S S S R S R R S S S S
834 11365 20 Primi II clear - - - - NG
835 8641 25 G2P1L1 III clear - - - - NG
836 545 23 Primi I clear - + - + Enterococcus faecalis + + R R R S S S S S S
837 3910 20 Primi I clear - - - + NG
838 1999 29 G3P2L2 II clear - - - - NG
839 2108 28 G2P1L1 II clear - - - - NG
840 6540 28 G2P1L1 II clear + + + - Escherichia coli + R S R S S S S R S S S S S
841 2112 27 G2P1L1 III clear - - - - NG
842 4481 20 Primi II clear - - - + NG
843 5019 22 G2P1L1 I clear - - - - NG
844 4671 37 G3P1L1A1 III clear - - - - NG
845 3079 20 G2P1L1 I clear - + + - Escherichia coli R R S S S S S S S R S S S
846 3339 26 G2P1L1 II clear - - - - NG
847 2873 24 Primi I clear - - - - NG
848 2248 20 Primi III clear - - - - NG
849 3264 21 Primi II clear - - - - NG
850 208 27 G2P1L1 II clear - - - - NG
851 42176 22 G2P1L1 II clear - + + + Escherichia coli + S S R S S S R R S S R S S
852 4015 22 Primi III clear - - - - NG
853 581 23 Primi II clear - - - - NG
854 645 19 Primi I clear - - - - NG
855 1771 26 G2P1L1 II clear - - - - NG
856 2256 38 G2P1L1 I turbid - + + - Escherichia coli R S R S S S S R S S S S S
857 2512 28 G2P1L1 II clear - - - - NG
858 1437 26 Primi III clear - - - - NG
859 658 23 Primi II clear - - - - NG
860 5701 24 G2P1L1 I clear - - - - NG
861 3183 25 G2P1L1 III clear - - + + Escherichia coli + + R S S S S R S S R R S S S
862 3452 18 Primi I clear - - - - NG
863 2670 22 Primi III clear - - - - NG
864 4340 27 G2P1L1 III clear + + + - Escherichia coli + + S S S S S S S R S R S S S
865 725 36 G2P1L1 II clear - - - - NG
866 16963 28 G3P2L2 II turbid - - - - NG
867 3680 23 Primi I clear - - - - NG
868 2801 21 Primi II clear - - - - NG
869 7632 20 Primi II turbid - + + + Escherichia coli R S R S S R S R R R S S S
870 12673 23 G3P0L0A2 I clear - + + + Escherichia coli R S R S S R S S R S S S S
871 2824 23 G2P1L1 I clear - - - - NG
872 65263 22 G2P1L1 I clear - - + + Escherichia coli + R R S S S R S S S S R S S
873 15254 33 G3P1L1A1 II clear - - + - Escherichia coli + + R S R R R S S R S S S S S ESBL
874 2812 22 Primi III clear - - - - NG
875 6530 24 G2P1L1 III clear - - - - NG
876 5553 22 Primi III clear - - - - NG
877 6253 20 Primi I turbid - + - + Escherichia coli R R S S S S S S R S S S S
878 3554 26 G2P1L1 II clear - - - - NG
879 5122 22 Primi I clear - - - - NG
880 12467 21 G2P1L1 II clear - - - - NG
881 12466 18 Primi I clear - - - - NG
882 5612 19 Primi III clear - - - - NG
883 43109 22 Primi I clear - + - - Escherichia coli R R R S S S S S S R R S S
884 5342 23 Primi I clear - + - - Staphylococcus aureus + + + + + + S S S R S S R S S R S S
885 6263 25 G2P1L1 II turbid - - - - NG
886 12679 27 G2P1L1 II clear - - - - NG
887 12523 34 G2P1L1 III clear - - - - NG
888 5231 27 G2P1L1 III clear - + + + Enterococcus faecalis + R S S S S S S R S
889 5243 20 Primi I clear - - - - NG
890 7614 25 G2P1L1 II turbid - - - - NG
891 62671 34 G2P1L2 I clear - + + + Escherichia coli S S S S S S S S S R S S S
892 2341 19 Primi II clear - + - - NG
893 4526 23 G2P1L1 II clear - - - - NG
894 19593 22 Primi I clear - - - - NG
895 5423 27 G2P1L1 III clear - + + - Staphylococcus saprophyticus R S S R S S S S R R S S
896 12611 18 Primi I clear - - - - NG
897 1527 25 G2P1L1 I clear - - - - NG
898 1E+05 30 G3P1L1A1 III turbid - - - - NG
899 44321 20 Primi I turbid - + - - Staphylococcus aureus + + + + + + S S S S R S S R S R S S
900 23410 37 G2P1L1 II clear - - - - NG
901 4531 28 G2P1L1 III clear - - - - Enterococcus faecalis + R R S S S R R S S
902 6034 19 Primi I clear - - - - NG
903 2432 24 Primi III clear - - - - NG
904 3258 30 G2P1L1 II clear - - - - NG
905 5309 20 Primi II clear - - - - NG
906 23561 19 Primi I clear - - - - NG
907 5364 21 Primi III clear - + + + Staphylococcus aureus + + + + + + R R R S S S S R R S S S
908 12654 35 G2P1L1 II turbid - - - - NG
909 2804 22 Primi III clear - - - - NG
910 2940 24 G2P1L1 I clear - - - - NG
911 3032 31 G2P0L0A1 II clear - - - - NG
912 2588 20 Primi III clear - - - - NG
913 19375 20 Primi II clear - - - - NG
914 4172 19 Primi I clear - - - - NG
915 3173 22 Primi III clear - - - - NG
916 62366 20 Primi I clear - + + + Enterococcus faecalis R S R R R R S S S
917 3035 20 Primi III clear - - - - NG
918 2335 20 Primi II clear - - - - NG
919 4390 25 G2P1L1 I turbid - - - - NG
920 3076 29 G3P1L1A1 I clear - - - - NG
921 3372 23 Primi III clear - - - - NG
922 15184 18 Primi II turbid - - - - NG
923 2614 28 G2P1L1 III turbid - - - - NG
924 3139 24 Primi I clear - - - - NG
925 648 25 Primi III clear - - - - NG
926 21889 21 Primi II clear - - - - NG
927 5537 24 G2P1L1 III clear - - - - NG
928 4591 20 Primi I clear - - - - NG
929 1031 32 G2P1L1 II clear - - - - NG
930 3527 23 Primi II turbid - - - - NG
931 1028 25 G2P1L1 III clear - - - - NG
932 23810 30 G2P1L1 III clear - - - - NG
933 3535 21 Primi II turbid - - - - NG
934 502 20 Primi II clear - - - - NG
935 3633 24 Primi III clear - - - - NG
936 2144 25 Primi II clear - - - - NG
937 3459 18 Primi III clear - - - - NG
938 3341 33 G2P1L1 II turbid - - - - NG
939 934 18 Primi I clear - - - - NG
940 1129 35 G2P1L1 III turbid - - - - NG
941 2625 21 Primi I clear - - - - NG
942 3357 18 Primi I clear - - - - NG
943 2478 26 G2P1L1 II clear - - - - NG
944 1214 23 Primi II clear - - - - NG
945 3741 22 Primi I turbid - - - - NG
946 25975 22 Primi II clear - - - - NG
947 3914 29 G2P1L1 I turbid - - - - NG
948 2711 23 Primi III clear - - - - NG
949 3944 20 Primi I clear - - - - NG
950 3667 26 G2p1L1 II turbid + + + - Escherichia coli + R S R S S S S S S S R S S
951 18131 30 G2P1L1 III clear - - - - NG
952 26715 23 Primi II clear - - - - NG
953 29062 28 G2P1L1 I clear - - - - NG
954 4015 21 Primi III clear - - - - NG
955 4329 25 Primi I turbid + - + + Escherichia coli + + S S S S S S S S R S S S S
956 27792 23 Primi III turbid - - - - NG
957 880 27 G2P1L1 II clear - - - - NG
958 3531 25 Primi II turbid - - - - NG
959 4182 25 Primi I clear - - - - NG
960 4592 22 Primi I clear - - - - NG
961 27597 25 G2P1L1 III turbid - - - - NG
962 4375 20 Primi II clear - - - - NG
963 3228 35 G2P1L1 I clear - - - - NG
964 4506 30 G2P1L1 III clear - - - - NG
965 9953 25 Primi II clear - - - - NG
966 5318 35 G3P2L2 III clear - - - - NG
967 3408 20 G2P1L1 III clear - - - - NG
968 4217 19 Primi I clear - - - - NG
969 2235 26 G3P1L1A1 III clear - - - - NG
970 46342 28 G3P1L1A1 III clear - - - - NG
971 12633 21 G2P1L1 I clear - - - - NG
972 2216 25 G3P2L2 II clear - - - - NG
973 4531 23 G2P1L1 III turbid - - - - NG
974 2097 38 G3P1L1A1 II turbid - - - - NG
975 2345 26 G3P0L0A2 II clear - - - - NG
976 2315 24 G2P1L1 III clear - - - - NG
977 3214 21 Primi I clear - - - - NG
978 4326 22 G2P1L1 I clear - - - - NG
979 2186 35 G4P2L2A1 II clear - - - - NG
980 4357 28 G2P1L1 III clear - - - - NG
981 2138 27 G3P2L2 II clear - - - - NG
982 1263 32 G3P2L2 II clear - - - - NG
983 3476 25 G2P1L1 I clear - - - - NG
984 7653 26 G3P1L1A1 I clear - - - - NG
985 2367 24 G2P1L1 II clear - - - - NG
986 4651 20 Primi I clear - - - - NG
987 4653 29 G3P1L1A1 III clear - - - - NG
988 2764 29 G4P1L1A2 II clear - - - + NG
989 3289 24 G3P0L0A2 I clear - - - - NG
990 5632 24 G2P0L0A1 II clear - - - - NG
991 1240 30 G4P1L1A2 III clear - - - - NG
992 2387 35 G3P2L2 II clear - - - - NG
993 3451 25 G2P0L0A1 II turbid - - - - NG
994 3570 28 G3P1L1A1 III clear - - - - NG
995 5243 24 G3P0L0A2 II turbid - - - - NG
996 1778 26 G3P2L2 II turbid - - - + NG
997 5631 23 G3P1L1A1 I clear - - - - NG
998 3475 20 Primi I clear - - - - NG
999 4520 20 G2P1L1 I clear - - - + NG
1000 3216 25 G2 P1L1 I clear - - - - NG
